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AID  activation-induced cytidine deaminase  
ADCC  antibody-dependent cell-mediated cytotoxicity 
APRIL  a proliferation-inducing ligand 
BAFF  B-cell-activating factor 
BCR  B-cell receptor 
CD  clusters of differentiation 
CDR  complementarity determining region 
CFU  colony forming units 
CSF  cerebrospinal fluid 
CXCL  CXC-chemokine ligand 
CXCR  CXC-chemokine receptor 
D  diversity 
DC  dendritic cell 
DNA  deoxyribonucleicacid 
DM  dermatomyositis 
EBV  Epstein-Barr virus 
eGFP  enhanced green fluorescence protein 
ER  endoplasmatic reticulum 
FACS  fluorescence-activated cell sorting 
FDC  follicular dendritic cell 
FR  framework 
GC  germinal center 
hc  heavy chain  
HCMV  human cytomegalovirus 
IBM  inclusion-body myositis 
IFN  interferon 
Ig  immunoglobulin 
IHC  immunohistochemistry 
IL  interleukin 
IM  inflammatory myopathies  
IRES  internal ribosome entry site 
J  joining 
κc  kappa chain 
λc  lambda chain 
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lc  light chain 
LTR  long terminal repeat 
mDC  myeloid dendritic cell 
MG  myasthenia gravis 
MOG  myelin oligodendrocyte glycoprotein 
MOI  multiplicity of infection 
MS  multiple sclerosis 
PC  plasma cell 
PCR  polymerase chain reaction 
pDC  plasmacytoid dendritic cell 
PF  perifascicular 
PM  polymyositis 
PNA  peanut agglutinin  
R  replacement mutation 
RA  rheumatoid arthritis 
RNA  ribonucleicacid 
RT  reverse transcriptase 
S  silent mutation 
SHM  somatic hypermutation 
SLE  systemic lupus erythematosus 


















Inflammatory myopathies (IM) can be divided into three distinguishable syndromes, 
dermatomyositis (DM), inclusion-body myositis (IBM), and polymyositis (PM). Current 
knowledge suggests DM to be a primarily antibody-mediated autoimmune disease. While the 
immunopathogenesis of IBM and PM appears to be mediated by cytotoxic CD8+ T-cells, IBM 
additionally shows signs of degenerative processes. However, recent data have 
demonstrated the presence of B cells and plasma cells in diseased muscle derived from DM, 
PM, and IBM patients. The major goal of this work was to characterize the repertoire of 
immunoglobulin (Ig) genes expressed by B- and plasma cells in IM to gain further insight in 
B-cell-dependent mechanisms possibly playing a role in the etiology of IM. In order to 
achieve this goal, we established a method permitting the isolation of individual plasma cells 
from muscle biopsy material followed by single-cell RT-PCR of Ig heavy and light chain 
genes.  
From forty-one IM biopsy specimens we identified eleven biopsy tissues, including samples 
from DM, IBM, and PM patients by means of immunohistochemistry, which contained CD19+ 
B cells and CD138+ plasma cells. Biopsies containing B- and plasma-cells were first analyzed 
by CDR3 spectratyping to obtain an overview of the clonal composition of the Ig repertoire 
contained in the biopsy material. Subsequently performed single-cell RT-PCR of Ig genes 
from laser-microdissected plasma cells revealed a strong clonal expansion of plasma-cell 
clones in IBM, whereas in DM and PM we found a more polyclonal Ig gene repertoire. While 
in IBM Ig heavy chain sequences derived from the same plasma-cell clone were mostly 
identical, some sequences derived from DM and PM showed signs of clonal variation. Some 
of the strongly expanded plasma-cell clones we identified in IBM tissue by single-cell RT-
PCR, we could confirm by the methodologically independent CDR3 spectratyping analysis. 
Our data provide insight into the Ig repertoire of infiltrating plasma cells in IM and indicate 
an antigen-driven immune response involving B cells in affected muscle, especially in IBM. 
Furthermore, the amplification of both Ig heavy and light chain genes from the same cell 
permits the recombinant resurrection of the original antibody specificity, providing a powerful 
tool to identify potential target antigens of muscle-directed, autoaggressive immune 
responses. Such tools should greatly enhance our understanding of IM immunopathogenesis, 









In der Krankheitsgruppe der inflammatorischen Myopathien unterscheidet man drei Formen: 
Dermatomyositis (DM), Einschlusskörpermyositis (inclusion-body myositis, IBM) und 
Polymyositis (PM). DM wird als eine primär Antikörper-vermittelte Autoimmunerkrankung 
angesehen, während bei IBM und PM zytotoxische CD8+ T Zellen für die Immunpathogenese 
verantwortlich zu sein scheinen. Bei der IBM sind zusätzlich degenerative Veränderungen 
nachgewiesen worden. Neue Erkenntnisse deuten darauf hin, dass B-Zellen und 
Plasmazellen, die vor kurzem im Immunzellinfiltrat bei allen inflammatorischen Myopathien 
nachgewiesen wurden, eine mögliche Funktion in der Pathogenese haben. 
Das Ziel der vorliegenden Arbeit war die Charakterisierung des B- und Plasmazell-Repertoires 
anhand der Analyse ihrer Immunglobulingene, und ihrer möglichen Funktion in der Ätiologie 
der IM. Dazu wurde eine Methodik etabliert, die die Isolierung von einzelnen Plasmazellen 
aus Muskelbiopsien und die Amplifikation der schweren und leichten Immunglobulin (Ig) 
Kettengene möglich macht. Aus einer grösseren Anzahl von Biopsien wurden elf Gewebe 
ausgewählt, in denen B- und Plasmazellen immunhistochemisch nachgewiesen werden 
konnten. Zunächst wurden B-Zell positive Biopsien mit Hilfe des CDR3-Spektratype 
Verfahrens analysiert, um eine Gesamtübersicht über die klonale Zusammensetzung des 
darin enthaltenden Immunglobulinrepertoires zu erhalten. Anschliessend wurden an 
ausgewählten Biopsien einzelne Plasmazellen mit Hilfer der Laser-Mikrodissektion isoliert und 
per Einzelzell-RT-PCR analysiert. Die Resultate der Einzelzell-RT-PCR der Immunglobulingene 
ergaben starke Expansionen von Plasmazellklonen in IBM-Geweben und ein eher 
polyklonales Immunglobulinrepertoire in DM und PM. Während die Analyse der schweren 
Immunglobulinkettengene der stark expandierten Plasmazellklone in IBM-Gewebe fast 
ausschliesslich identische Sequenzen aufwiesen, zeigten einige aus DM and PM Gewebe 
amplifizierte Sequenzen die Zeichen von klonaler Variation. Einige der stark expandierten 
Plasmazellklone im IBM Gewebe konnten mit der methodisch unabhängigen CDR3-
Spektratype Methode bestätigt werden.  
Unsere Daten geben Aufschluss über das Immunglobulinrepertoire der Muskel-infiltrierenden 
Plasmazellen und deuten auf eine Antigen-induzierte humorale Immunantwort insbesondere 
bei der IBM hin. Darüberhinaus erlaubt die Amplifikation der schweren und leichten Ig 
Kettengene aus derselben Zelle die Wiederherstellung der ursprünglichen Antigenspezifität 
des von dieser Plasmazelle sezernierten Antikörper durch rekombinante Expression. Diese 
Technik kann die Identifizierung von neuen Zielantigenen bei Myositiden ermöglichen, unser 
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Wissen über die Immunpathogenese der IM vergrössern und möglicherweise Wege für die 
































1.1 The humoral immune system 
 
1.1.1 Biology of B cells 
 
The adaptive immune system, containing T-lymphocytes, B-lymphocytes and their secreted 
antibodies as key elements, plays an important role in eliminating foreign microorganisms 
and molecules that may otherwise compromise health and wellbeing. B lymphocytes arise 
from hematopoietic stem cells and, after a clonal selection process, mature to produce 
antibodies specific to an antigen. In the bone marrow, stem cells mature independent of an 
antigen into pro-B cells, pre-B cells, and immature B cells, which enter the antigen-
dependent phase of development in the peripheral lymphoid tissues (Figure 1).  
1.1.2 Antibodies 
 
Antibodies are the effector molecules of B cells which are located on the cell-surface or can 
be secreted. They are able to bind surface antigens of pathogens, such as fungi, bacteria, 
and viruses and contain two different functional parts, the antigen-binding fragment (Fab), 
and the constant fragment (Fc), which interacts either with other immune cells or activates 
the complement cascade to opsonize and finally eliminate the pathogen. Antibody molecules 
are heterodimers consisting of two heavy-chain and two light-chain molecules which are 
joined by disulfide bonds. There are antibodies of IgM isotype, which can also form 
pentamers. Each chain has a variable region and a constant region (Han et al., 1995). The 
variable region is responsible for the binding of antigen. The heavy chain (hc) is comprised 
by three constant regions CH1-CH3 and one variable region; the light chain (lc) by one 
variable and one constant region. The variable region of light chains consists of a 
combination of alleles from only two families (V) and (J) which can originate from two 
different genetic loci (kappa or lambda). The hypervariable region of hcs is generated by 
recombination of three different genetic elements: The variable (V), diversity (D), and joining 
(J) gene segment (Early et al., 1980).  
The diversity of the immunoglobulin repertoire is established by four processes. First, by the 
recombination of three or two gene segments, which constitute the V-region of heavy and 
light chains, respectively. In these recombination events, different gene segments are 
randomly combined (combinatorial diversity). Second, junctional diversity is generated 
during recombination by addition or depletion of nucleotides at the joints between different 
gene segments. Further diversity is generated by the combination of different heavy- and 
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light-chain variable regions. Combinatorial and junctional diversity leads to the generation of 
approximately 1011 different  receptors. Finally, somatic hypermutation (SHM) introduces 
mutations into the variable region genes during affinity maturation and increases further the 
diversity of the antibody molecules. The constant region is responsible for the effector 
functions of the antibody. This part of the antibody is coded by mainly five different C region 
genes and determines the isotype.  
 
1.1.3 Antigen-independent development in the bone marrow 
 
The development of lymphocytes in mammals takes place in highly specialized environments 
of the central lymphoid organs. B cells and T cells originate from hematopoetic stem cells in 
the bone marrow. Later T cells migrate into the thymus. Both immune cell subset 
development is characterized by gene rearrangement of their receptors. The state of 
development of both cell types can be determined by their rearrangement status. After 
reaching adolescence, T cells no longer develop in the thymus, but in peripheral lymphoid 
organs. B cells are produced lifelong in the bone marrow. In both specialized lymphoid 
compartments non-lymphoid cells, so-called stromal cells are present which are essential for 
the development of the B and T cells and interact with these cells through the secretion of 
growth factors and expression of signaling molecules on their cell surface (van Ewijk, 1991; 
Funk et al., 1994).  
Some of these bone marrow-derived factors and their functions are known. For example the 
growth of early B-lineage cells is induced by stem cell factor (SCF), a membrane-bound 
cytokine present on stromal cells. This factor interacts with the cell-surface receptor tyrosine 
kinase (Kit) on B-cell precursors. Later in development other factors are required, like the 
cytokine interleukin-7 (IL-7) or the chemokine stromal-cell derived factor-1 (SDF-1) 
(Nagasawa et al., 1996).  
The antigen specificity of each individual T cell and B cell is determined by the 
rearrangement of V-, D-, and J-gene segments. The expression of the whole receptor 
molecule of a B cell requires the successful rearrangement of two gene loci, one for the 
heavy chain and one for the light chain immunoglobulin gene. A successful rearrangement 
(productive rearrangement) leads to the entry of the cell into the next stage of development. 
An „out-of-frame rearrangement“, which does not lead to protein expression is called a non-
productive rearrangement and leads to apoptosis. The individual stages in primary B-cell 
development are defined by the sequential rearrangement and expression of heavy and light 
chain immunoglobulin genes (Janeway CA et al., 2001).  
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The first classification is made by the expression of either heavy chain alone (pre-B cell) or 
heavy and light chain (immature B-cell) expression.  
 
The earliest B-lineage cells are called pro-B cells. They are derived from pluripotent 
hematopoietic stem cells and are identified by expression of characteristic cell surface 
markers e.g. MHC class II, CD10, and CD19. In this stage, the DH to JH rearrangement in the 
early phase takes place. At a later stage the VH to DHJH joining takes place. Productive 
rearrangement leads to the expression of a functional heavy chain, which characterizes pre-B 
cells. These cells express the heavy chain in combination with a surrogate light chain. Pre-B 
cells start to rearrange the light-chain locus and, after successful joining, a complete IgM 
molecule is expressed. The cells are now called immature B cells (Hardy et al., 1991). 
 
1.1.4 Antigen-dependent development in the periphery 
 
The entire development up to this stage has taken place within the bone marrow, 
independent of antigen. Now immature B cells are selected for self-tolerance and the ability 
to survive in peripheral lymphoid tissues. Only 50% of the pre-B cell population emerges 
from primary development in the bone marrow. It is assumed that this is due to the failure in 
making a productive light-chain rearrangement. Most peripheral B cells are long-lasting and 
only 1-2% of these cells die every day. The immature B cells, which circulate outside the 
bone marrow, are further tested for self-tolerance and look for survival niches within B-cell 
follicles in secondary lymphoid organs, like the lymph nodes. In these follicles, follicular 
dendritic cells (FDCs) and T-helper cells provide B cells with survival signals. If immature B 
cells are unable to get into these follicles, 50% of the population dies within 3 days. Because 
of the low probability that a helper T-cell will find the appropriate B cell, it was long a major 
question as to how this might happen. It is assumed that when an animal is immunized with 
an antigen, the antigen is captured, processed, and presented in context with MHC class II 
molecules on professional antigen presenting cells, such as dendritic cells. These cells 
migrate until antigen encounter into the T-cell zones of lymph nodes. Naive circulating T cells 
migrate through such lymph nodes and encounter dendritic cells which present their antigen. 
A mechanism similar to that of T-cell trapping is assumed for the trapping of B cells. On 
encountering their antigen, B cells are arrested by the activation of adhesion molecules and 
the engagement of chemokine receptors (such as CCR7). In this manner antigen-binding B 
cells are precisely trapped in the correct location to maximize the probability of encountering 
a helper T-cell which activates them. The interaction with helper T cells activates the B cell 




Figure 1. Development of B cells (adapted from Dalakas et al. 2006). 
When these positively selected B cells are re-stimulated with the relevant antigen, clonal 
expansion takes place. This leads to mature (naive) B cells expressing surface IgM and IgD, 
later developing into activated B cells, in the germinal center into memory B cells or early 
and late plasmablasts. Plasmablasts finally mature into antibody-producing PCs that are all 
specific for the original antigen (Figure 1) (Goldsby R.A. et al., 2000; Avery et al., 2005; Sell 
and Max, 2001). Specific cluster of differentiation (CD) markers such as CD19 and CD20 















1.1.5 Germinal center reaction 
 
Some B cells and T cells which have proliferated within the primary focus migrate into a 
primary lymphoid follicle, where they continue to proliferate and form a germinal center 
(GC), which serves as a cellular environment for the improvement of affinity through SHM 
and class switch recombination of immunoglobulin genes. A GC is a complex cellular 
aggregate of many different cell types. This specialized microenvironment can be divided 
into a dark zone with rapidly dividing centrocytes and a light zone in which small centrocytes 
are in contact with a network of FDC processes. Antigen-specific helper T-cells which are in 
strong contact with proliferating GC B cells as well as follicular dendritic cells (FDCs) which 
present antigen on their surface are important for the GC response (Manser, 2004).  
T-helper cells in the GC express CXC-chemokine ligand 13 (CXCL13) (Kim et al., 2004) at 
high levels to recruit B cells to the GC and the adaptor protein SAP (signaling lymphocyte-
activation molecule (SLAM)-associated protein), which is required for providing help (Crotty 
et al., 2003). 
Interactions between the B-cell receptor, CD40 ligand and CD40 and inducible T-cell co-
stimulator (ICOS)-ICOS ligand which are present at the cell surface of helper T- and B cells 
take place to maintain the GC reaction (Bishop and Hostager, 2001). The signals from the B-
cell receptor and CD40 are assumed to upregulate the expression of Bcl-XL which prevents 
apoptosis of B cells. FDCs sequester antigen in the GC for which complement receptors 
(CD21 and CD35) expressed by FDCs are crucial. (Barrington et al., 2002). It is assumed that 
such sites of antigen persistence are survival signals for long-lived PCs. 
Antigen-specific B cells that participate in the GC reaction expand rapidly and downregulate 
their germline encoded BCR (MacLennan, 1994). The clonal expansion is accompanied by 
BCR diversification through SHM (Jacob et al., 1991; Berek et al., 1991). Interestingly, SHM 
has also been demonstrated outside GC (Matsumoto et al., 1996; William et al., 2002). SHM 
is characterized by the introduction of single base-pair substitutions with rare insertions and 
deletions into the variable regions of antibody gene segments. The main enzyme involved in 
this process is the recently discovered activation-induced cytidine deaminase (AID) (Revy et 
al., 2000). B cells which have improved their affinity receive further survival signals, whereas 








1.1.6 Ectopic germinal center reaction 
 
Affinity maturation of B cells and the final development into either a memory B cell or a PC 
usually takes place in secondary lymphoid organs, for example in lymph nodes or in the 
spleen. In several autoimmune and also infectious diseases however, structures are present 
in the affected organs that resemble GCs, for example, in diarthrodial joints in rheumatoid 
arthritis (Takemura et al., 2001), the thyroid gland in Hashimoto´s thyroiditis (Armengol et 
al., 2001), the thymus in myasthenia gravis (Roxanis et al., 2002), the salivary glands in 
Sjogren´s syndrome (Amft et al., 2001), and the meninges in multiple sclerosis (Prineas, 
1979; Serafini et al., 2004) as examples for autoimmune diseases. They are also found in 
chronic inflammatory diseases, e.g. in the gut in Crohn´s disease (Carlsen et al., 2002), and 
also in infectious diseases in the stomach in Helicobacter pylori induced gastritis 
(Mazzucchelli et al., 1999). These structures are called ectopic GCs or tertiary lymphoid 
organs. They are characterized by the presence of B cells, PCs, T cells, FDCs, and high 
endothelial venules, as well as by the expression of the chemokines CXCL12 and CXCL13. 
See as an overview of an ectopic GC development figure 2. For more information see review 
article (Aloisi and Pujol-Borrell, 2006). 
The genetic analysis of V-genes from B cells, isolated from GC-like structures, has shown 
SHM. It is assumed that these B cells mature at such ectopic sites into PCs and produce 
















Figure 2. Schematic model of cellular and cytokine–chemokine networks in the initiation of 
inflammation and in the development of chronic inflammation and lymphoid neogenesis (adapted 
from Aloisi et al. 2006).  
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1.2 B cells and autoimmunity 
1.2.1 Plasma cells 
 
After several days of proliferation of both B cells and T cells, the primary focus begins to 
disappear and many lymphocytes comprising the focus undergo apoptosis. However a small 
fraction of dividing B cells will differentiate into antibody-synthesizing PCs and migrate to the 
red pulp of the spleen or the medullary cords of the lymph nodes. PCs can further develop 
from naive marginal-zone B cells, from follicular B cells, from activated GC B cells, and from 
memory B cells (Shapiro-Shelef and Calame, 2005). 
The differentiation into PCs is mediated by the activation of Blimp-1, a transcriptional 
repressor (Turner, Jr. et al., 1994) downregulating the expression of two transcription 
factors that are required for GC reactions, BCL-6 (Shaffer et al., 2002) and PAX5 (Lin et al., 
2002), thereby ensuring that, once PC development has been initiated, B cells cannot return 
to an earlier developmental stage. PCs are highly Ig-secreting cells, with abundant cytoplasm 
containing multiple layers of rough endoplasmic reticulum. Ig makes up 10-20% of 
synthesized protein. The surface expression of Ig is still present but very low. It seems 
necessary for the PC to bind antigen on the surface to receive survival signals. PCs lack 
surface expression of MHC class II molecules but are still sensitive to signals like IL-6 and 
CD40L. PCs have different life spans, which may vary between days and several years 
(Janeway CA et al., 2001). 
 
1.2.2 Plasma cells and autoantibodies 
 
Recent literature provides evidence for the involvement of B cells in the immunopathogenesis 
of autoimmune disorders, such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), and myasthenia gravis (MG) (Drachman, 1994; Lipsky, 2001; Edwards et al., 1999). 
Under physiological conditions the human immune system produces by random 
recombination of V-, D-, J-gene segments antibodies which are autoreactive. This 
phenomenon is suspected to help in maintaining the optimal functioning of the immune 
system. There are tolerance-inducing mechanisms at key points of B-cell development. If 
these regulatory mechanisms are compromised, loss of self-tolerance may be of disease 
initiating consequence.  
In the past, the role of B cells in autoimmunity has been associated mainly with the ability of 
PCs and plasmablasts to produce self-damaging antibodies. These autoantibodies may bind 
to self-antigens and may interfere normal cellular functions and/or lead to tissue destruction 
e.g. by activating the complement cascade. Examples are, the deficit of acetylcholine 
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receptors in MG or the deposition of autoantibodies against basement membrane collagen 
type IV in the kidney and lung alveoli in patients with Goodpasture`s syndrome or anti-
glomerular basement membrane (GBM) syndrome, induces glomerulonephritis and 
necrotizing hemorrhagic interstitial pneumonitis by complement activation and recruitment of 
immune cells (Dalakas, 2006a). In dermatomyositis (DM) it is assumed that antibody-
induced complement activation leads to destruction of muscle capillaries, thus inducing the 
characteristic perifascicular atrophy seen in DM biopsies (Dalakas and Hohlfeld, 2003). 
 
Furthermore, B cells participate in immune reactions not only by autoantibody production, 
but also by activating immune cells through secretion of proinflammatory cytokines, antigen 
presentation and complement activation. For example, B cells activate the secretion of IL-6, 
TNF-α, and IL-10 by macrophages and modulate the function of other immune cells 
(Fillatreau et al., 2002; Duddy et al., 2004; Chan et al., 1999; Weinstein et al., 2004; 
Goldsby R.A. et al., 2000). 
Through antigen presentation to naive T cells, B cells can stimulate their antibody 
production, by direct interaction as well as by cytokine production (Constant, 1999). This 
interaction can  lead to the expansion of B cells and T cells which recognize the same 
epitope in parallel. This phenomenon has been shown for the recognition of myelin basic 
protein (MBP) epitopes in MS patients (Wucherpfennig et al., 1997). The Fc portion of an 
antibody can also bind to its receptor on macrophages, neutrophils, and NK cells. These 
activated cells attack the specific tissue by antibody-dependent cell-mediated cytotoxicity 
(ADCC). 
BAFF, a potent B-cell supporting factor, plays a role in such diseases by activating the 
expression of oncogenes like Bcl-2 (Mackay and Tangye, 2004). Bcl-2 expression leads to the 
survival of B cells. In the context of autoimmune-diseases it can be hypothesized that 
uncontrolled BAFF expression can lead to the survival of autoreactive B lymphocytes. 
Increased BAFF expression has been observed in the CNS of MS patients (Krumbholz et al., 
2005).  
Depletion of B cells in autoimmune diseases by an anti-CD20 antibody rituximab 
(MabThera®; Rituxan®), is beneficial in RA and is currently being tested in other autoimmune 
disorders including multiple sclerosis. This treatment does result in a decrease of 
autoantibody concentration (RF), whereas the total Ig serum levels decrease only slightly. 
Additionally, levels of pneumococcal-polysaccharide-specific antibodies are not changed 
during treatment, because these antibodies are derived from marginal-zone B cells which 
seem not to be targeted by rituximab (Edwards et al., 2004).  
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1.2.3 Plasma-cell migration and survival niches 
 
PCs migrate from secondary lymphoid organs to the bone marrow via blood or the lymphatic 
system. There is ever-growing understanding of the mechanisms which direct cells to 
homage sites. Adhesion molecules, such as VLA-4, VLA-5, CD9, CD44, and CD138 (Arce et 
al., 2004; Ridley et al., 1993; Wehrli et al., 2001), are present on the PC surface and are 
assumed to be involved in their homing and survival in specific tissues.  
Also, chemokine receptors play a role in regulating the migration and survival of PCs which 
are attracted by the expression of CXCL12, the ligand for CXCR4 in the red pulp of the 
spleen, medullary cords of lymph nodes, and the bone marrow stroma (Hargreaves et al., 
2001). While on plasmablasts CXCL12 has a migration-stimulating effect, PCs respond by 
prolonged survival (Hauser et al., 2002). 
The signals which are present in the bone marrow for long-term survival are not completely 
understood. Some factors, however, have been identified which prolong survival, such as IL-
5, IL-6, CXCL12, SDF-1α, and TNF-α (Roldan and Brieva, 1991; Wols HAM et al., 2002; 
Cassese et al., 2003). 
CXCR3 is another chemokine receptor which is expressed by PCs (Hauser et al., 2002; Manz 
et al., 2002). The corresponding ligands (CXCL9-CXCL11) are expressed in inflamed tissues 
and by some high endothelial venule cells, which are present in the draining lymph nodes of 
B-cell follicles (Janatpour et al., 2001). PCs are present in chronically inflamed tissues 
















1.3 Inflammatory myopathies 
 
The inflammatory myopathies (IM) can be divided into three distinguishable syndromes: 
polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM) (Dalakas and 
Hohlfeld, 2003; Dalakas, 2004). 
DM leads to proximal muscle weakness and skin changes, affecting both children and adults. 
PM is a rare disease affecting mostly adults and leads to proximal muscle weakness, as well. 
IBM mostly affects adults and is characterized by proximal and distal muscle weakness. Its 
progression is slow. All three disorders are characterized by an inflammation of the 






















In DM, the intramuscular capillaries are characterized by endothelial hyperplasia with 
tubureticular profiles, vacuolization, and necrosis, which is thought to cause ischemia and 
the characteristic muscle-fiber atrophy at the periphery of muscle fascicles (perifascicular 
myofiber atrophy see figure 3) (Kissel et al., 1986). The serum level of the muscle specific 
creatine kinase, which is released from necrotic muscle fibers is increased, and correlates to 
disease activity. Complement deposition and activation of C5b-9 membrane attack complex 
on endomysial blood vessel walls and additionally of immune complexes consisting of Ig and 
complement C3 are part of the first-occurring immunopathological changes which lead to 
destruction of capillaries.  
Figure 3. Perfascicular myofiber atrophy in dermatomyositis  
muscle (adapted from Dalakas et Hohlfeld 2003). 
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B cells are a frequently found cell type within the cellular infiltrate in DM, which is also 
characterized by high CD4/CD8 ratio and B cell and CD4 T-cell synapses, which would 
suggest a CD4 T cell-induced Ig secretion by B cells (Hohlfeld and Engel, 1994). One general 
hypothesis in the pathogenesis of DM is tissue damage by way of autoantibody-mediated 
complement activation (Dalakas and Hohlfeld, 2003; Whitaker and Engel, 1972; Kissel et al., 
1986). 
Additionally, perifascicular fibers express MHC class I antigens and various IFN-γ or α and β 
induced markers, such as CD56 and amyloid beta precursor protein (ABPP). The 
inflammatory cellular infiltrate also contains plasmacytoid dendritic cells (pDCs) (Greenberg 
et al., 2005b). These histological findings and data from microarray experiments indicate a 
type 1 IFN-driven immune response and also suggest an innate immune response in contrast 
to the long-established antibody-mediated autoimmune paradigm in DM. 
 
1.3.2 Inclusion-body myositis and polymyositis 
 
In PM and IBM cytotoxic CD8+ T-cells are thought to be responsible for muscle fiber 
destruction (Dalakas and Hohlfeld, 2003). These cells are localized around and inside MHC 
class I antigen-expressing non-necrotic muscle fibers. In both diseases the muscle fibers are 
thought presenting antigen and form immunological synapses with the T-cell receptors of 
clonally expanded CD8+ T-cells (Hofbauer et al., 2003). In PM as well as in DM, it was 
demonstrated that perforin is expressed in muscle infiltrating T cells (Goebels et al., 1996). 
However, only in PM a vectorial orientation of intracellular perforin containing granula onto 
myofibers have been demonstrated, suggesting perforin to be an important effector molecule 
in the pathogenesis of PM. The infiltrating and long-persisting CD8+ T cells are in an 
activated state because they express CD45RO, ICAM, ICOS, and MHC class I antigen. The 
upregulation of MHC class I antigen expression on the target cell is typically found in PM and 
IBM and induced by cytokines. In noninflammatory chronic myopathies the class I antigens 
are absent (Michaelis et al., 1993; Wiendl et al., 2005). The MHC class I expression is 
present on every muscle fiber in IBM and PM, regardless of whether they are surrounded, 
invaded, or free of inflammation. This observation suggests two processes in parallel: 1. a 
cytotoxic T-cell response triggered by MHC class I presentation and the presence of 
costimulatory molecules. 2. a non-immune process which is characterized by ER stress 
induced by overexpression of MHC class I antigen (Dalakas, 2006c). 
In PM and IBM, the data suggests a HLA-restricted, antigen-specific, T-cell-mediated 
myocytotoxicity. Therefore, the CD8+ T cells presumably recognize antigens, which are 
expressed and processed in the endogenous pathway of antigen presentation, by the 
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antigen-presenting cell itself. It is further assumed that these proteins may be viral 
components or from self (Hohlfeld and Engel, 1994). Until now, there is no evidence for the 
presence of viral antigens or genomes in muscle fibers (Leff et al., 1992; Dalakas, 2006b). 
This would argue for a T cell-mediated autoimmune response in PM and IBM. 
In IBM, diagnostic markers are the presence of filamentous inclusions (which contain 
myxovirus nucleocapsids), and of 15-21nm cytoplasmic tubulofilamentous inclusions which 
consist of ubiquitin and the accumulation of 6-10nm β-amyloid-like filaments (Massa et al., 
1991; Askanas et al., 1991). The presence of ABPP, microtubule-associated protein tau and 























Figure 4. Cross-section of a muscle from a patient with IBM 
Note two red-rimmed vacuolated fibers (yellow asterix) not invaded by inflammatory cells. These 
vacuolated fibers contain degeneration-associated molecules, such as ABPP, ubiquitin, or tau. Adapted 






































                          
                  
                      
 
Figure 5. Infiltration of immune cells in IBM and PM. 
Above: Endomysial inflammation in polymyositis and inclusion-body myositis with lymphocytic cells 
invading myofibers (yellow asterix). 
Below: The MHC-I/CD8 complex in polymyositis and inclusion-body myositis. MHC-I (green) is 
upregulated on muscle fibers, and CD8-positive T cells (orange), that also express MHC-I, invade the 




1.3.3 Inflammatory myopathies and humoral immunity 
 
All three diseases are assumed to be (auto-) immune mediated diseases in which the target 
antigens have not been identified. Greenberg et al. have recently shown that the immune 
cell infiltrate in inflammatory myopathies may also contain plasma cells (Greenberg et al., 
2005a). Recently, the infiltrating PC repertoire in DM and IBM was analyzed by generating 
cDNA libraries of heavy chain Ig genes from inflammatory myopathy tissue. The analysis of 
the immunoglobulin variable region sequences indicates an antigen-driven immune response, 
indicated by clonal expansion of B cells and affinity maturation, which is characterized by the 
insertion of replacement mutations within the Ig sequences. Analyses of B cells from 
different tissue regions show clonal variation, which the authors discuss as a clue of affinity 
maturation within the muscle tissue itself and outside from classical sides of GC reaction 























1.4 Identification of antigens by expression cloning 
In our lab we generate recombinant human antibodies derived from expanded plasma-cell 
clones from several presumed autoimmune diseases like multiple sclerosis, myasthenia 
gravis and inflammatory myopathies. The final goal of these studies is the identification of 
the target antigens and the analysis of their pathophysiological relevance. Therefore, we 
sought to generate a system in which possible target antigens are expressed in a structure 
as similar to the human system as possible.  
The cellular processes comprise an enormous number of specific protein-protein and protein-
DNA interactions for the cellular functions of e.g. protein expression, cell-cycle and cell-cell 
interaction, and connected signaling pathways. One major goal in cell biology is the 
knowledge of all molecular interactions of a cell. This would lead to the development of new 
compounds for the treatment of diseases. To discover interacting partners and ligands 
several approaches over the last two decades have been developed. 
 
The identification of binding partners for distinct target molecules is one of the main goals in 
molecular biology. It is also relevant for the development of drugs, in which molecules have 
to be identified for their impact on cellular interactions. For this reason, different methods 
have been developed to achieve these goals. The more simpler systems use cDNA libraries 
generated from a target tissue or cell type and cloned into prokaryotic vectors for the 
expression in bacteria. Other systems utilize lambda phages for the generation of 
fusionproteins with phage core proteins. The advantages of such systems are that they are 
easy-to-handle and well-established. However, proteins expressed in prokaryotic libraries 
have a number of disadvantages such as the absence of posttranslational modifications and 
proper folding of proteins. More advanced mammalian expression cloning systems using viral 
mediated gene transfer have been established recently (Koller et al., 2001). 
The main advantages are the introduction of the transgene into the genome and the 
resulting stable expression of the protein. Furthermore, viral infection allows the adjustment 
of the infection rate per cell to approximately one insertion of the retroviral construct into the 
genome per cell. That allows the identification of antigens more easily compared to 
transfections in which high copy numbers of plasmids can enter one cell and protein 
expression will be lost after a short period of time. We therefore planned to generate an 
expression system, in which cDNA libraries of human origin are retrovirally transferred and 





1.5 Goal of this work 
 
The initial aim of this thesis was to characterize the B- and plasma-cell infiltrate in 
dermatomyositis, the one IM which had traditionally been assumed to be antibody and 
complement-mediated. The recent finding of infiltrating PCs in all three IM disorders 
encouraged us to also include PM and IBM in our studies. Using two different methodological 
approaches, we aimed to characterize the clonal composition of the B and plasma-cell 
infiltrate in IM muscle specimens. The two methods we chose are complementary: CDR3 
spectratyping is a molecular tool which gives an overview on the total clonal composition 
contained in the tissue volume analyzed, based on the CDR3 length distribution of expressed 
VH chain genes. On the contrary, the single-cell RT-PCR analysis can only be performed on a 
limited number of individual plasma cells excised by laser microdissection from tissue 
sections. Yet it allows to obtain both immunoglobulin heavy and light chain gene sequences 
from individual plasma cells, which is the basis to reconstruct the antigen specificity of their 
secreted immunoglobulins by means of expression as recombinant monoclonal antibodies. 
These antibodies could then be used to screen expression libraries derived from IM mRNA 
for their cognate target antigen(s) and to identify the possible role of the humoral immune 


























2 Materials & Methods 
 
2.1 Biopsy collection 
 
Muscle specimens obtained from biopsies were provided by the Friedrich-Baur-Institute, 
University Hospital Munich. Muscle biopsies were performed for clinical indications, 




The immunohistochemistry was performed by the „Labor für Spezialtechniken“ at the 
Department of Pathology (University Hospital Zurich). Following antibodies were used: CD3, 









2.3 Immunofluorescene stainings 
a) Double immunofluorescence staining of CD138 / HLA-DR 
 
Myositis tissue (snap frozen) was cut into 10μm thick sections using a cryotome (Leica) at -
25°C. After a two-step fixation in acetone 50% v/v in water for 30s followed by 100% 
acetone for 5 minutes at 4°C, sections were washed in TBS pH 7.6 and incubated with 
normal goat serum (5% v/v in antibody diluent, Dako Cytomation) for 30 minutes at room 
temperature (RT). Endogenous Biotin was blocked by applying Streptavidin Solution 
(Avidin/Biotin blocking kit, Vector Laboratories) for 15 minutes and after rinsing incubated 
Antigen  Cell specificity  Clone  Dilution  Detection system  Source 
CD 3  T cells  SP7  1:100  Ultra View DAB  Labvision 
CD 4  T cells  1F6  1:30  Ultra View  Medite 
CD 8  T cells  C8/114B  1:100  Ultra View  Dako  
CD 20  B cells  L26  1:100  Dako En Vision  Dako 
CD 68  macrophage  PG‐M1  1:50  Ultra View  Dako 
CD 138  Plasma cells  MI15  1:30  Ultra View  Dako 
IgA  B cells  polyclonal  1:20.000  iView DAB  Dako 
IgG  B cells  polyclonal  1:15.000  iView DAB  Dako 
IgM  B cells  polyclonal  1:5.000  iView DAB  Dako 
(PNA)  GC B cells  na  1:400  Vectastain Elite HRP  Vector 
 
Table 1. Antibodies used for immunohistochemistry.
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with Biotin Solution for 15 minutes. After two steps of washing with TBS, sections were 
incubated with biotinylated mouse anti-CD138 (clone B-B4, Diaclone) antibody diluted 1:25 
in antibody diluent (Dako) and anti-HLA-DR FITC (Dako) antibody diluted 1:25 for 2 hours at 
RT. After two steps of washing (2x 10 minutes in TBS), sections were further incubated with 
a Streptavidin-594 (Alexa Fluor 11227, Molecular Probes) conjugate diluted 1:700 in antibody 
diluent. The sections were washed twice (10 min) in TBS, incubated with Hoechst dye to 
stain the nucleus, then finally washed and embedded in Medi-Mount (Medite). 
 
b) Staining of plasma cells for laser microdissection application 
 
Snap-frozen tissue specimens were cut into 10μm- to 12μm-thick sections, using a cryotome 
(Leica) at -25°C. Tissue pieces were placed onto metal frame slides (Molecular Machines), 
then thawed for approximately 10s at room temperature. The staining procedure was done 
according to the protocol of the HistoGene LCM immunofluorescence staining Kit (Arcturus). 
Tissues were fixed in acetone (Merck) on ice for 2 min. The slide was kept at room 
temperature until the acetone had evaporated completely, then put onto a metal plate 
cooled on ice. The tissue section was circumscribed using a PapPen (Dako) and rehydrated 
with staining buffer. Biotinylated anti-CD138 antibody (clone B-B4, Diaclone) was diluted 1:4 
in staining buffer and after adding Prime RNase inhibitor (Eppendorf) to an final 
concentration of 2U/μl applied to the tissue for 4 min. After three washing steps (adding 
each time 150μl of ice-cold staining buffer), the section was incubated with Cy3-Streptavidin 
1μl diluted in 200μl of staining buffer (Arcturus Kit) for one minute. After three more 
washing steps as described above, the section was dehydrated for 30 seconds each in 70%, 
95%, and 100% ethanol. After 5 min clearing in xylene, the section was dried for 10 min and 













Figure 6. Overview of slide preparation for LM.
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2.4 CDR3 spectratyping 
 
This PCR-based method gives insight into the clonal composition of a lymphocyte population. 
It is based on the natural length polymorphism of the CDR3 region of hc Ig genes. As an 
output of this method the distribution of the different VH genes is given according to the 
nucleotide length of their CDR3 region. In the case of a polyclonal VH repertoire, the VH 
sequence-length representation would lead to a Gaussian distribution (Figure 7), if the y-axis 
represents the relative concentration and the x-axis the nucleotide length of the PCR 
products in the amplicon, whereas a clonally expanded VH repertoire would be represented 
as single peaks on the plot. The clonal composition can be analysed at the VH and JH family 
levels. Spectratyping permits the detection of clonal distribution with a resolution of each VH 
























Figure 7. Principle of CDR3 spectratyping.  
Left: Schematic drawing of the CDR3 region: Random insertion of (non genomically encoded) N-nucleotides 
between the genomically encoded V-, D-, and J-regions during the process of somatic recombination leads to 
a natural length polymorphism of the CDR3 region of the rearranged T-cell receptor beta chain and 
immunoglobulin heavy chain gene. (modified according to Gorski et al., 1995). 
Right: Example of CDR3 spectratyping patterns. Whereas the three panels on the right show the typical 
Gaussian distribution of polyclonal B-cell populations, the three left panels show examples of strongly 
expanded B-cell clones (shown here is the analysis of CSF cells from an MS patient).
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For CDR3 spectratyping approximately 15 sections (each of 10μm thickness) were cut using 
a cryotome, and lysed in Trizol (Invitrogen) for the isolation of total RNA. Trizol containing 
lysed tissue, was incubated for 5 min at RT, chloroform was added and vigorously shaken. 
After 5 min incubation at RT the sample was centrifuged (14.000rpm, 4°C) for 15 min. The 
aqueous phase was removed and transferred to a new reaction tube after adding 1μl of 
glycogen (Invitrogen). After brief mixing, 700μl of 70% (v/v in water) isopropanol was added 
and incubated for at least 20min at -20°C. Afterwards the sample was centrifuged again at 
14.000rpm at 4°C for 20min. The supernatant was discarded and to the precipitate 1ml 
ethanol 80% (v/v in water) was added. After a final centrifugation step a  14.000rpm at 4°C 
for 5min, supernatant was removed again and the RNA pellet was dried at RT and 
resuspended in 12μl RNase-free water. Oligo dT primed RNA was reverse-transcribed using 
Superscript II reverse transcriptase (Invitrogen) at 42°C for one hour.  
 
PCR reactions for the amplification of immunoglobulin genes were performed using six 
forward primers (VH1RK-VH6RK) in combination with reverse primers either binding to the 
constant region of IgG or IgM. Each reaction was conducted in 50μl of 1x PCR buffer 
(AmpliTaq Gold), 2mM MgCl2 containing 20mM dNTPs, 1,25μM primers, 1U of AmpliTaq 
Gold, and 1,0μl cDNA as template. Amplification was performed according to the following 
cycling conditions: after 6 min of denaturation at 94°C, 44 cycles of 94°C for 1 min, 63°C for 
1 min, and 72°C for 1 min were performed, followed by a final extension at 72°C for 7 min. 
For fluorescence labeling of the different J-families, four different fluorescently labeled J-
primers (JH 1.2, JH 3, JH 4.5, and JH 6) were introduced by “run-off” PCR. One PCR reaction 
was performed in a volume of 30μl. This reaction mixture consisted of 1x PCR-Puffer (Ampli 
Taq), 0,4mM dNTPs, 1,2 U Ampli Taq Gold and 0,03mM primer. The PCR was performed 
according to the protocol: after 10 minutes of denaturation at 94°C, 4 cycles of 94°C for 1 
min, 59°C for 1 min, and 72°C for 10 min were performed. The “run-off” products were then 
separated on sequencing gels. Using automated DNA sequencer and the Immunoscope 









2.5 Laser microdissection of CD138 positive plasma cells 
 
For laser microdissection an inverse Olympus fluorescence microscope (adapted to a laser 
microdissection unit (Molecular machines, Glattbrugg) was used. To remove cells from the 
tissue section a modified tube with a volume of 0.2ml was placed with its special adhesive lid 
onto area of interest and single infiltrating PCs were marked on the computer screen and 
automatically cut out by a UV laser beam. Laser velocity, focus and laser energy were 
adapted to optimal cutting performance. After cutting, the tube with the lid containing the 
single cell was removed from the cap holder. Then 25μl of buffer, consisting of 1x buffer, 
2U/µl Prime RNase Inhibitor, was inverted and put immediately on dry ice. 
 
2.6 Single-cell RT-PCR of microdissected plasma cells 
 
Single laser-microdissected PCs were lysed in 25μl of RT-buffer containing 2U/μl RNase 
inhibitor. The appropriate volume of enzyme mix was added to the sample and transferred to 
0,2ml PCR tubes (Eppendorf).  
For the preparation of enzyme mix for amplification of IgG and IgM heavy-chain 
immunoglobulin genes or heavy- and light-chain immunoglobulin genes from one single cell, 
the following concentrations of components were used: 1x buffer containing 10mM dNTPs, 
0,2μM of each forward primer and reverse primer, 2U/μl RNase inhibitor, and 1.2 (two 
reactions hc IgG and IgM) or 1.5 μl (three reactions hc IgG or IgM with lc) of enzyme mix. 
The primers for the amplification of Ig genes were used and modified according to (Carlos 
F.Barbas III et al., 2001). 
For the amplification of IgG and IgM hc (or IgG hc and corresponding lc or IgM hc and 
corresponding lc) from single cells, 5μl (or 13μl for three reactions) of mix were added to the 
sample and distributed in 14μl (or 12μl) reaction volume to PCR tubes (0,2ml) containing 
prepared primer mixes. RT-PCR were performed with Eppendorf Mastercycler device 
according to the following cycling program: 50°C for 60 min, 95°C for 10 min, 45 cycles of 
95°C for 30s, 58°C for 45s, and 72°C for 1 min were performed, followed by a final 








2.7 PCR product purification and sequencing 
 
PCR products were separated by agarose gelelectrophoresis. Samples were loaded onto a 
agarose gel 1,2% (weight/volume) in TBE (Tris-Borate-EDTA) buffer pH 8 and performed at 
180V for approximately one hour. After documentation (geldoc) PCR products of calculated 
size were cut out. Nucleic acids were purified from gel excisions using the MinElut PCR 
purification Kit from Qiagen.  
Purified PCR products were adjusted to a concentration of 10ng DNA per μl, the appropriate 
reverse primer was added and sequenced at Synergene Biotech.  
Sequence data from Ig genes were analyzed using DNA Star MegAlin, SeqMan, and IMGT 
online software tools. 
 
2.8 Cloning and expression of antibodies 
 
After sequence analysis of the first PCR product for Ig hc, Ig κc, or Ig λc, a second PCR 
reaction was performed with specific V region and J region primers containing restriction 
sites for cloning into expression vectors. Three different vectors were used for the expression 
of the hc IgG and the corresponding lc. The vector backbone contains a leader sequence, an 
human cytomegalovirus (HCMV) promoter region and an ampicillin resistance gene. Each 
vector additionally contains the constant regions for hc, κc or λc. The vectors and inserts 
were digested with AgeI and SalI (hc), BsiwI (kc), or XhoI (lc). After the ligation reaction 
and transformation of E. coli, clone sequences were compared to the first PCR product.  
The eukaryotic cell line, 293T, grown in Dulbecco's Modified Eagle's Medium (DMEM; 
GibcoBRL) supplemented with 10% heat-inactivated ultralow IgG fetal calf serum (FCS) 
(Invitrogen) 100 μg/ml streptomycin, 100 U/ml penicillin G were seeded onto 150mm plates. 
At 80% confluency, cells were transfected using the calcium-phosphate precipitation 
method. Twelve hours post transfection the medium was replaced by serum-free D-MEM 
media supplemented with 1% Nutridoma SP (Roche). After 8 days in culture the supernatant 
was harvested and recombinant antibodies were purified by affinity chromatography using 
protein G sepharose (Amersham Bioscience). For a detailed description of recombinant 
antibody production see (Tiller et al., 2008). 
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2.9 Construction of a cDNA expression library 
 
For the construction of recombinant cDNA libraries the Cloneminer Kit from Invitrogen was 
used. All procedures were performed according to the manufacturer’s protocol. 
In brief, poly A+ RNA (BD Biosciences) from different CNS areas (whole brain, spinal cord, 
corpus callosum) and skeletal muscle was used. First-strand synthesis was performed by 
using SuperScriptTM II reverse transcriptase (Invitrogen). mRNA was primed with an Biotin-
attB2-oligo(dT) primer which hybridizes to the 3’ mRNA poly(A) tail. After second-strand 
synthesis using E. coli DNA polymerase I and blunt-end ligation of the GatewayTM adapter 
molecule attB1 to the 5’ end the cDNA was size-fractionated with exclusion of fragments 
smaller than 500bp by size-exclusion chromatography to remove truncated cDNA and non-
ligated adapter molecules. The cDNA was flanked by attB sites (recognition sequences for 
lambda phage recombination enzymes) to circumvent, on the one hand, restriction digest 
and ligation and, on the other hand, to allow the recombination of the whole library cDNA 
inserts into an entry-vector for amplification. After plasmid purification the cDNA library was 
transferred via a second recombination reaction into an expression vector of choice. For 
quality analysis the number of primary clones was calculated, and single cDNA clones were 
sequenced (Figure 8).  
 
Our intention was to induce transgene expression in mouse cell lines. After protein 
expression had occurred, the cells would have been stained with labeled recombinant 
antibodies and analyzed by FACS sorting. Positively stained cells would have been sorted into 
wells and regrown. To identify the expressed transgenes, the genomic DNA would have been 
extracted and a PCR using vector specific primers performed. The product would have been 
sequenced and should reveal the identity of the transgene expressed in this particular cell 
clone. In the case of a non-membrane-associated protein the cells could have been stained 
intracellularly. In this case, the cells cannot be regrown, so that a sufficient number of cells 
















































Figure 8. Principle of cDNA library construction. 
This figure illustrates the general principle of the construction of a retroviral cDNA expression library. mRNA 
from different tissue sources is reverse transcribed and by a first recombination reaction recombined into an 
entry vector. In a second recombination reaction the cDNA library inserts are transferred into an retroviral 
expression vector. After amplification of the cDNA library in E. coli the plasmid DNA is used for the production 
of ecotrophic virus by transfection of a packaging cell line. After harvesting the viral supernatant, mouse cell 
lines can be used for infection. 
 
 
Figure 9. Principle of antigen identification. 
This figure shows the strategy for antigen identification. Target cell lines are infected by retrovirus containing 
the cDNA library transcripts. After protein expression the infected cells are stained by the antibody, for which 
the antigen specificity will be determined. After FACS sorting of stained cells, the antigen can be determined by 
PCR of the proviral DNA and subsequent sequencing.
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2.9.1 Retroviral expression vectors 
 
As retroviral expression vector, pQCXIP was used from BD Bioscience. For transferring the 
cDNA library from the entry library vector into the expression vector, a GatewayTM 
recombination cassette was blunt-end ligated and cloned into the multicloning site of the 
vector. Transcripts which are inserted into pQCXIP vectors are bicistronically transcribed with 
an IRES-Puromycin sequence. As control vectors we recombined eGFP and MOG into the 
retroviral expression vector pQCXIP. eGFP was amplified from another vector by using 
specific primers with flanking attB sites. MOG was purchased already recombined in a 
Gateway entry vector (Invitrogen). 
 
2.9.2 Virus production and retroviral infection of mammalian cells 
 
After generation of a cDNA library from total human brain RNA, the cDNA was transferred to 
retroviral vectors as described, and retroviral packaging cell lines were transfected to 
generate mouse specific viral supernatant.  
One day before transfection of the packaging cell line, 1.4 x 107 cells were seeded on a 
150mm cell culture plate in 25ml media. After 80% confluency had been attained, cells were 
transfected by calcium-phosphate precipitation method. Therefore 50μg of retroviral plasmid 
DNA was diluted in 1mM Hepes solution. CaCl2 was added to a final concentration of 250mM 
and a final volume of 750μl. After that, 750μl HeBS were dropwise added to the plasmid DNA 
and incubated for 10min at room temperature. The cells were transfected by adding the 
precipitate and then incubating for at least 6 hours. One day post transfection the exhausted 
media were replaced by fresh media. After 48 and 72 hours the retroviral supernatant was 
harvested centrifuged at 500g for 5min and the supernatant stored at -80°C. (For detailed 






































The primary goal of our study was the analysis of the clonal composition of the PC repertoire 
in inflammatory myopathies (IM). Muscle biopsy specimens of patients with IM were 
obtained from the Friedrich Baur Institute, University Hospital Munich. For each patient, the 
diagnosis of an IM was established according to current clinical and histological criteria. 
Table 2 summarizes all important information concerning patient history and the results of 
the histological analysis characterizing the inflammatory infiltrate present in the biopsy. In 
most cases the obtained material was from the first performed biopsy. If the patient was 
treated with immunosuppessive agents at the time the biopsy was taken it is noted in the 
table. Creatine kinase (CK), an enzyme released from muscle fibers as a consequence of 
muscle destruction, is commonly used as a parameter for disease activity in IM. CK activity is 
listed in the biopsy summary table 2. We analyzed all biopsies by immunohistochemistry for 
the presence of B- and PCs. The histological analysis gave us information about the extent of 
inflammation and about the composition of the cellular infiltrate, as well. In most cases a 
medium to high infiltration by CD4+ T cells and CD8+ T cells was present. The presence of B 
 
 




cells and/or PCs was found not to be a general feature of every IM biopsy. We could detect 
PCs in 2 of 6 PM, in 8 of 25 DM and in 7 of 10 IBM biopsies. In general, the number of PCs 
was higher than that of B cells. In PM only one CD138+ biopsy also contained infiltrating 
CD20+ B cells. In DM and IBM all CD138+ biopsies also contained B cells in different 
quantities (Figure 10). To characterize the PCs further with respect to their Ig isotype, we 
performed stainings for three different isotypes IgG, IgM, IgA. IgG, and IgM were the 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2 Identification of plasmablasts and terminally differentiated plasma 
cells 
 
The first developmental change of GC B cells is the transient plasmablast state. These cells 
are CD138 positive, express high amounts of MHC class II, still divide, and secrete Ig in high 
amounts. Terminally differentiated PCs no longer divide and are characterized by low MHC 
class II expression. To determine the developmental state of the PCs in IM double-
immunofluorescence stainings with an anti-CD138 and an anti-HLA-DR were performed to 
distinguish between plasmablasts and PCs. The presence of plasmablasts would indicate the 
presence of active GCs. In all IM, PCs, but not plasmablasts, were detected (Figure 11). This 
finding does not indicate the presence of active GCs with proliferating plasmablasts, 
however, we can not exclude the presence of such GCs in other areas of the inflamed 
muscle. 
Additionally, we tried to detect GCs in the biopsy material by histological analysis. To identify 
GC B cells we performed a peanut agglutinin (PNA) staining. But, we could not detect any B 
cells which were stained by PNA (data not shown). The CD19 staining shows some 
infiltrating B cells (see table 2) and, in three tissues, cluster like accumulations of B cells, 
which are typical but do not provide conclusive evidence for the presence of GCs. 
So far, we have no evidence for the presence of GCs in IM biopsies which have been used 
for PC repertoire analysis. In some biopsies clonal variations have been observed indicating 




















































Figure 11. Immunofluorescence staining for the identification of plasmablasts and plasma cells. 
CD138 staining in red; HLA-DR staining in green. Merge A CD138 and HLA-DR; Merge B CD138, HLA-DR and Dapi 
The overlay of stainings for CD138+ PCs and MHC class II shows no colocalization in any of the IM biopsies. This 
finding clearly shows that the CD138+ cells are terminally differentiated PCs.  
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3.3 Characterization of the B-cell infiltrate by CDR3 spectatyping 
 
After obtaining information about the extent of B lymphocyte infiltration and their Ig isotype, 
we were interested in overall clonal composition of the B- and plasma cells present in the 
tissue. Therefore, we analysed cDNA derived from several sections of the biopsies indicated 
in table 1, by complementarity determining region 3 (CDR3) spectratyping. This method 
allows the identification of clonally expanded B cells as individual “peaks” in the CDR3 length 
spectragram, whereas polyclonal populations give rise to a Gaussian-like distribution of the 
CDR3 spectragram. The basis of this method is an unbiased amplification of all heavy chain 
(VH) region genes present in the tissue. As an output of this method the distribution of the 
different VH genes is given according to the length of their CDR3 region. The clonal 
composition is analysed at  the VH and JH family levels. Spectratyping permits the detection 
of clonal composition with a resolution of each VH and JH Ig families. For more information on 
CDR3 spectratyping see (Pannetier et al., 1995). These spectratype experiments were done 
to complement LM as an independent technique for a clonal repertoire analysis  
Furthermore, we used this data to verify our data generated by LM. In the case of strongly 
expanded Ig populations it often is possible to directly determine the identity of the 
expanded clone by cycle sequencing. A strongly expanded clone detected in LM should be 
represented as one distinct peak in the spectragram and should also yield the same CDR3 
sequence as that obtained from sc RT-PCR of excised PCs. The CDR3 spectratype analysis 
were performed in collaboration with the Max Planck Institute for Neurobiology in Munich. 
As an example of a biopsy with a polyclonal hc repertoire represented as a Gaussian-like 
curve in the spectragram is DM 354/03 (Figure 12), an oligoclonal repertoire with distinct 















































Figure 12. CDR3 spectragram of DM 354/03. 
This figure shows the CDR3 length spectragrams for VH1-6 families. The peak height correlates to the 
relative abundance. The spectragrams for IgG are shown. In A the spectragrams for VH1 and the different 
JH families are shown (top down) VH1-constant region IgG, VH1-JH1,2, VH1-JH3, VH1-JH4, 5, VH6-JH6; In 






















































Figure 13. CDR3 spectragram of IBM 451/96.  
The figure shows the CDR3 length spectragrams for VH1-6 families. The peak height correlates to the relative 
abundance. The spectragrams for IgG are shown. In A the spectragrams for VH1 and the different JH families 
are shown (top down) VH1-constant region IgG, VH1-JH1,2, VH1-JH3, VH1-JH4, 5, VH6-JH6; In B the 







3.4 Characterization of the plasma-cell infiltrate by LM and sc RT-PCR 
 
Our major goal in this project was the analysis of Ig gene rearrangements from infiltrating B- 
and PCs in diseased muscle from IM. Our intention was further the reconstruction of the 
original antigen specificity of antibodies secreted by these PCs. For this purpose, it was 
necessary to amplify both heavy and light chain Ig genes from individual cells, to maintain 
the right pairing of the chains, which is necessary for the reconstruction of the original  
antigen specificity by recombinant expression.  
In our case, we were interested in the amplification of Ig transcripts from coding mRNA, 
because these transcripts are present in high quantities in PCs, and should serve as sufficient 
template for three different PCR reactions: heavy chain, light-chain kappa and light-chain 
lambda Ig. 
A genomic approach was not followed because of only one coding sequence per cellular 
genome and additionally because of the presence of introns which would lead to a very long 
PCR product. There are some limitations when RNA is used instead of DNA. The first and 
most important limitation is the biological instability of RNA, which is based on the presence 
of RNA degrading enzymes in the cell itself and also in the environment. For this reason, the 
biological material (biopsy) has to be isolated from the patient under RNA preserving 
conditions. A second reason is that, after cutting the tissue into sections, the cellular 
compartmentalization is destroyed, and RNases may degrade the RNA. Therefore all further 
steps have to be performed under conditions in which the RNA integrity is well preserved. 
Additionally, RNA is more instable than DNA because of its chemical nature. 
At the beginning of the thesis work it was therefore a major goal to establish a fast and 
efficient staining of immune cells, the dissection of single cells from stained dehydrated 
tissue sections and the amplification by RT-PCR of heavy- and light-chain immunoglobulin 
genes from single cells in which these conditions are maintained. For LM we used an 
inverted microscope with the device for dissecting tissue sections by UV laser. This 
microscope allows the efficient excision of cells in an acceptable time frame. The lid of a 
reaction tube was inverted over the area in which the PCs were present. After cutting, the lid 
was removed from the tissue area, and the cell remaining on the lid was put into buffer.  
In the following procedures, after LM, the activity of RNases has to be inhibited during the 
lysis step as well as in the gene-specific reverse transcription of the RNA.  
A lysis step is introduced to set free most of the RNA content from the fixed tissue section. 
We used tonsil tissue for establishing all steps. Because of the high risk of introducing DNA 
contamination, all steps were performed in separate rooms. RT-PCR reactions were set up in 
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a specially designated separate clean room with filtered air. Processing isolated PCs was the 
previous performed work before entering potential contaminated lab rooms. Special lab coats 
were weared to avoid cross-contamination. After establishing the method using tonsil tissue 
we had an efficacy of up to 60% for the RT-PCR reactions of single isolated PCs. Similar 
efficacies were reached for the reactions performed on PCs from IM biopsy samples. In a 
first LM experiment, RT-PCRs were set up for the amplification of hc transcripts of IgG and 





























3.5 Summary of all LM experiments 
 
After amplification of the heavy- and light-chain sequences of individual dissected cells, 
isolated products were sequenced. This allowed us to determine the CDR sequences, which 
are the highest variable sequence parts within the Ig gene and are responsible for antigen 
binding. In the sequence tables the experiment is indicated, the number given to each 
isolated PC and the usage of the V, D and J segments with the percentage of identity to the 
closest germline sequence (supplementary table page 85ff). 
The CDR3 regions of hc and lc are mainly responsible for the antigen specificity of the 
(corresponding) antibody. The framework region serves as a scaffold for the three CDR 
regions. Table 4 summarizes all LM experiments performed with biopsies from all three IMs. 
In summary we dissected over one-thousand single PCs. The general efficacy of the PCR was 
in a range of 26.0% to 61.5%. From each biopsy we obtained 23 to 82 hc sequences of 
either IgG or IgM isotypes. The most prominent clonal expansions were found in three IBM 
tissues, especially in IBM 451/96 in which we detected eight expanded clones. Obtained 
expanded clones were verified by amplification of the same hc sequence in independent 
experiments performed at different times. In IBM approximately 40% of all amplified 
sequences belonged to expanded clones, whereas in DM and PM only 20% of all sequences 
where expanded. For detailed information on the nucleotide composition of all amplified hc 
























































































































































































































































































































































































































































































































































































































































































































































































We isolated 230 PCs from this tissue. With a PCR efficacy of 36% we obtained 82 hc 
sequences of IgG isotype. PCRs for IgM heavy chain Ig were not performed because almost 
all PCs were of IgG isotype identified by IHC. The number of unique sequences was thirty-
seven, from which eight were highly expanded. The percentage of expanded sequences 
were 54,3% of all amplified sequences; 45,6% of all sequences were not identified as 
expanded. All sequences contained SHM whether expanded or not. The expanded hc 
sequences were identical to each other at the nucleotide level. Only one clone showed two 




Of 65 microdissected PCs, thirty-nine hc products could be amplified (efficacy: 60.0%). 
Seven sequences were of IgG isotype (17,9%). All other sequences were of IgM isotype. The 
sequence repertoire contained three expanded clones from which one was very highly 
expanded (32/40). The number of clones with different CDR3 region was five. All expanded 
sequences from individual clones were identical in their nucleotide sequence. 
 
IBM 373/96 
Twenty-eight hc products have been amplified from isolated cells from IBM 373/96. Twenty-
two different clones were obtained from which three clones were clonally expanded and 
identical in their nucleotide sequence. 
 
IBM 243/06 
In three experiments we amplified 33 heavy-chain sequences. We identified two expanded 
clones, which were identical in sequence. 
 
IBM 323/06 
This fourth IBM biopsy comprises 45 hc sequences amplified from 98 dissected PCs (efficacy 
46%). Three expanded clones, from which one clone had a quantity of three and two were 
found two times in the repertoire, were detected. Within these clones we found one clone 
which was identical to the secondly amplified sequence and two other clones showed 






From this DM biopsy 100 cells were dissected and 38 sequences amplified. The efficacy was, 
at 37%, somewhat low. Twenty-two sequences were of IgM isotype, and sixteen of IgG 
isotype. Two IgG clones and two IgM were both clonally expanded. One IgM and one IgG 
clone differed in several nucleotides from each other.  
 
DM 289/95 
From the second DM biopsy 27 hc sequences were amplified from 60 dissected samples 
(efficacy: 45%). From these sequences six were IgM, and twenty-one of IgG isotype. Two 
sequences were twice amplified and of identical sequence. 
 
DM 354/03 
Sixty-four sequences were amplified from 100 samples. We obtained 25 sequences of IgG 
and 39 of IgM isotype. In summary, we found five clones which were clonally expanded, two 
of them were identical, and three showed sequence variation. 
 
DM 354/98 
Seventy samples of the fourth DM biopsy were amplified and, with an efficacy of 52%, 
yielded 36 IgG sequences. We amplified three expanded and identical clones twice for each 
clone in the repertoire. 
 
PM 350/95 
From 110 dissected cells, 32 hc products were obtained. The efficacy was 29%. Most of the 
sequences were of IgG isotype. Five sequences were clonally expanded, and one of them 
showed clonal variation. 
  
PM 249/06 
From this biopsy, 59 samples were dissected and 22 heavy-chain sequences were obtained. 








3.6 Verification of expanded plasma-cell clones identified by sc RT-PCR 
Since we analyzed the Ig hc sequence repertoire in IM by two independent methods, we 
were able to verify our results. LM and subsequent sc-PCR are very sensitive methods and 
are highly susceptible to producing artifacts. CDR3 spectratyping is not only suitable to 
reveal the distribution of the CDR3 length of Ig hc genes, but can also serve as the basis for 
sequencing of single peaks which represent expanded clones in the spectragram.  
In both LM and CDR3 spectratyping experiments, we identified prominent clonal expansions 
in IBM 451/96 and IBM 379/96. We analysed the CDR spectragrams for peaks corresponding 
to expanded clones identified by sc-PCR and could amplify and sequence from CDR3 
spectratype amplicons using family specific primers of the corresponding hc sequence. With 
this approach we verified two highly expanded clones of IgG isotype from IBM 451/96 and 


























Figure 14a. Expanded clone from IBM 451/96 
Upper panel: CDR3 spectragram with indicated VH and JH families; middle panel: sequence from 
amplified spectratype peak, above CDR3 aminoacid sequence; lower panel: sequence from LM with 






































Figure 15. Expanded clone from IBM 379/96. 
Upper panel: CDR3 spectragram with indicated VH and JH families; middle panel: 
sequence from amplified spectratype peak, above CDR3 aminoacid sequence; lower panel: 
sequence from LM with date of experiment and cell number. 
 
 
Figure 14b. Expanded clone from IBM 451/96 
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3.7 Clonal variation of expanded plasma-cell clones 
 
During B-cell maturation the sequence of the Ig genes is modified by the process of affinity 
maturation. This reaction, which under normal physiological conditions takes place in a GC, 
involves a selection process for the highest affinity of the antibody to its antigen. The 
sequence of the CDR3 and framework regions is mutated by the activity of AID, which 
induces SHM and also class switch recombination (Muramatsu et al., 2000). This reaction 
generates a population of mutated clones which are related in sequence but differ in the 
number of mutations. 
In our Ig sequence collection from PCs isolated from IM biopsies we have identified eleven 
cases of clonal variation. This phenomenon was present in five biopsies (DM 354/03 n=3, 
DM 14/06 n=3; IBM 323/06 n=2, IBM 451/96 n=1; PM 350/95 n=1). In one clonal variation 
group, two to three related sequences were present. The occurrence of such variation 
suggests that these cells underwent a GC reaction which is antigen-driven. In figure 8, one 
example of a clonal variation is shown. Differences in the mutational pattern between the 
clones allow the reconstruction of the developmental steps of the clonal variation family 
members. An interesting finding in this context was that the expanded clones in IBM 451/96 
were with one exception completely identical in sequence. In one clonal variant group, two 
very similar but not identical clones were found and are shown in figure 16. In comparison to 
the closest germline sequence, cell 3/061212 is more similar than are cells 22/070521 and 
23/070521. The precursor of cells 22 and 23 is cell 3 which sequence was found twelve 
times in isolated PCs. The mutations are mainly located in the CDRs.  
The alignment shown in figure 17 contains three completely different mutational patterns. 
One can only determine the distance from the closest germline sequence, but cannot bring 
the sequences in relation to each other, because they do not share any mutations and clones 























































Figure 16. Alignment of clonal variants from IBM 451/96. 
Upper panel: Alignment of nucleotide sequences with comparison to the closest germline sequence  

















































Figure 17. Alignment of clonal variants from DM 354/03. 
Upper panel: Alignment of nucleotide sequences with comparison to the closest germline sequence  
(-): identical nucleotide. 
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3.8 Mutational analysis 
 
In peripheral lymphoid organs, further processes take place to increase the affinity of the 
antibody to its antigen, which is called affinity maturation. Mutations which are introduced in 
the CDRs could have an effect on the antigen specificity. If mutations within the sequence 
result in an amino acid change they are called “replacement mutations” (R), if the amino acid 
sequence is not changed, they are called “silent mutations” (S). Only replacement mutations 
might have an effect on the affinity when they target the CDRs. Therefore, the mutation 
pattern and nature (replacement vs. silent) are a fingerprint of affinity maturation, and its 
analysis gives us important information about the function of the PCs in IM.  
 
We analyzed the mutational distribution within the VH sequence, as well as its frequency and 
also its character in the sequence collection of IBM 451/96. By comparison of the ratio of 
replacement to silent mutations in CDR regions and framework regions from clonally 
expanded and polyclonal sequences, we can assume that an antigen-driven process took 
place (Qin et al., 1998). We analyzed the R and S mutations in hc sequences from IBM 
451/96. We compared the ratio of R- versus S- mutations within the expanded sequence 
group and the single occurring sequences. We found the ratio of R/S mutations in the 
framework and the CDRs is higher in expanded clones than in polyclonal sequences (Table 


















 non exp. clones exp. clones
Mut R/S (Fr)  2.4 4.6
Mut R/S (CDR) 3.6 7.0
Table 5. Ratio of replacement versus silent mutations 
(R/S) in Framework 1-3 and CDR1-3 from plasma cells  





Because of the fact that each cell is individually isolated by LM we not only have the 
information of the expressed Ig gene of a each cell, but also know its location within the 
tissue, as well. We are, therefore, able to reconstruct the immune cell topology at the time 
when the biopsy was performed. In the case of IBM 451/96, we determined eight highly 
expanded clones together with their positions in the tissue sections. We can conclude from 
this topology established over six independent experiments, that the clonally expanded PCs 
with identical Ig gene are not randomly distributed, but are preferentially found in distinct 
areas of the tissue section. When we divide the section into quadrants we can determine 
locations in which the different expanded clones are present. By performing several LMs of 
adjacent sections, we can show clones in the same location, which verifies our finding. For 
example, clone 1 (yellow) and clone 2 (blue) are mainly found in quadrant 1, whereas clone 




























































    






































Figure 19. Overview of three LM experiments.  
The left pictures show an overview of the tissue section used for LM. The detailed view shows the positions of 
the isolated plasma cells. The numbers in yellow and blue designate excised cells belonging to the same clone.  
White numbers not underlined indicate cells which did not yield a PCR product. White numbers underlined 





3.10 Cloning and expression of antibodies 
 
After having amplified the hc and lc sequences from several expanded PC clones from IBM 
451/96 and 379/96, we started to clone the PCR fragments into eukaryotic expression 
vectors. See expanded clones from IBM 451/96 with corresponding light-chain amino acid 
sequence listed below (Table 6) and expanded clones from IBM 379/96 (Table 7). The 
recombinant antibodies are currently being produced in mammalian cells, as described 




























Clone  CDR3 amino acid sequence V D J Frequency 
1 hc C A R N T Y Y F G S G S V S N Y S Y C A M D V W  V1-2*02 D3-10*01 J6*02 11/81 
 lc C Q Q Y G S P P P T T F  V3-20*01 n. a. J5*01  
2 hc C A R D E S S S N K S R R R R F D P W  V1-18*01 D3-22*01 J5*02 7/81 
 lc n. d.     
3 hc C A R G K R G A R D N Y F D Y W  V1-18*01 D1-14*01 J4*02 3/81 
 lc n. d.     
4 hc C A R R G R L D S T S R F Y F D F W  V3-74*01 D6-19*01 J4*02 4/81 
 lc C S S H A G G D N G Y V L F  V2-11*02 n. a. J2*01  
5 hc C V Q D T V T N L N Y S F A S W  V3-9*01 D4-17*01 J4*02 15/81 
 lc C S S Y I T S T T L E G H V V F  V2-14*01 n. a. J2*01  
6 hc C A K C G P F G G V M V I P F D Y W  V3-23*04 D3-16*01 J4*02 4/81 
 lc C Q Q Y H T L P P L T F  V1-33 n. a. J4*01  
7 hc C V R D G Y C T S A N C Y F F Q H W  V3-33*01 D6-13*01 J4*02 5/81 
 lc C Q Q G F S P P L T F V1-39*01 n. a. J4*01  
8 hc C A R N S H G G R S S D A F D I R  V3-33*01 D1-26*01 J3*02 3/81 
 lc C Q Q F N S Y P R T F  V1-13*02 n. a. J5*01  
 
Table 6. CDR3-sequences of clonally expanded PCs from IBM 451/96. 
The table lists all expanded heavy chain sequences from IBM 451/96 and if determined the light chain sequence as 
well. The different V, D and J families are listed for every clone and the quantity of each clone as well. Underlined 
numbers indicate that the corresponding antibody currently being expressed. Colored numbers refers to figure 19 




































Clone  CDR3 amino acid sequence V D J Frequency 
1 hc  C N V V G R D G G S S S P H W V3-15*01 D4-23*01 J4*02 32/40 
 lc C Q Q Y Y T T L L T F V4-1*01 n. a. J4*01  
2 hc C A R G V C S G G T C L G Y W V3-74*02 D2-15*01 J4*02 2/40 
 lc C H Q Y Y N T P F T F V4-1*01 n. a. J3*01  
3 hc C A R E A P E G D C T T I S C Y R Y N G M D V W V1-69*01 D6-13*01 J6*02 4/40 
 lc n. d.     
 
Table 7. CDR3-sequences of clonally expanded PCs from IBM 379/96. 
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3.11 Construction of a mammalian cDNA expression library 
 
We generated size-fractionated, non-normalized, non-full length selected cDNA libraries. 
During cDNA library construction small DNA fragments (<500bp) were strongly reduced by 
size-exclusion chromatography. The cDNA libraries were not normalized to reduce the 
amount of highly expressed genes and increase that of low expressed transcripts.  
The number of clones prior to library amplification was at least 0.5-1.0 x 107 colony forming 
units (cfu) as determined by plating out E. coli containing cDNA in serial dilutions. The 
primary library was maintained in a cloning plasmid for maintenance in bacteria (E. coli). 
Since we attached attB sites (recognition sequences for lambda phage recombination 
enzymes) to the cDNA, the whole library could be recombined into an entry-vector for 
amplification and via a second recombination reaction into an expression vector of choice. By 
performing recombination reactions the need of using restriction enzymes is avoided, which 
might have cut within the cDNA transcript.  
As an expression vector the retroviral vector pQCXIP was used and modified by insertion of a 
Gateway recombination cassette. The transgenes are bicistronically transcribed via an 
internal ribosome entry site (IRES) puromycin selection marker. This allows the selection of 
infected cells.  
The human brain library recombined into the expression vector was amplified using 280 x 
150mm LB plates for generating plasmid DNA for the transfection of the packaging cell line. 
As packaging cell line the high titer ecotrophic retrovirus producing cell line 293T Phönix Eco 
was used (Pear et al., 1993), which has been stably transfected with a Moloney Gag-Pol-
IRES-Lyt2 construct. These cells were then stably transfected with Moloney ecotropic 
envelope gene (see Materials and Methods). The expression vector contains only the 
packaging signal sequence and the Long terminal repeats (LTR) for the insertion into the 
mammalian genome. 
The main advantage of a retrovirally mediated gene transfer is the stable integration of the 
transgene (proviral DNA including the Long terminal repeats (LTR)) into the genome and the 
control of number of integrated sequences per cell, by adjusting the multiplicity of infection 
to 0.5 per cell. These advantages make the transgene analysis of cells more feasible 
compared to transient transfections, in which the copy number cannot be adapted and 
transgene expression will decrease over time. Transient transfections of cells are easier to 
perform, but the high copynumber of vector molecules per cell (20-100) makes identification 
of the transgene impossible.We have generated several different libraries. As an example, 
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the results of one cDNA library constructed from whole brain RNA is shown below. The 
number of primary clones was 1.0 x 107 cfu.   
For the verification of a successful and effective recombination reaction restriction digests 
were performed. The amount of clones containing a cDNA insert was above 90% (Figure 
20). 
From a limited number of clones, sequence reactions were performed to determine brain 























Table 8. Results of sequence analysis of cDNA library clones. 
In this table the size of the cDNA insert, as well as the blast result with the corresponding size according to the 






Figure 20. Restriction digest of cDNA library clones.  
Restriction digest of plasmid DNA from cDNA library clones. As restriction enzyme BsrGI was used, which cut 
5’ and 3’ of the multicloning site. The digested empty vector is visible in lane 1.
Sample Name Size gel (kb) Identity Size Blast (bp) Gen Bank Full Length 
Lib sc 01 2 Myelin basic protein 2156 BC047521 no
Lib sc 02 3.6 
Colony stimulating 
factor Rezeptor  3904 BC047521 yes 
Lib sc 03 2 
Ras related small 
GTPase 2042 BK001232 yes 
Lib sc 04 3 Proteolipid-protein 2777 M27110 yes
Lib sc 09 2 Myelin basic protein 2156 BC047521 yes
Lib sc 12 0.5 nd na na na
Lib sc 13 2 myelin basic protein 2156 BC047521 yes
Lib sc 14 2.1 
Tyrosine kinase 
receptor (trk-e) 3554 X74949 no 
Lib sc 15 2.1 unknown na 
BAC RP13-
82066  na 





Lib sc 22 2.8 
Glial fibrillaric acid 
protein 3035 NM002055 no 




As positive control vector constructs, the cDNA transcript of eGFP and MOG was recombined 
into the same retroviral expression vector as for the human brain cDNA library expression. 
Transgene expression was analyzed after puromycin selection of the infected mouse cell line. 
As expected almost all cells were infected with either eGFP or MOG (Figure 21A). These 
constructs were important controls for the functionality of the expression system. They 
served as control constructs during production of retroviral particles containing library cDNAs 
and infection experiments with library virus. However these control experiments are of 
limited value, because cells have been infected with only one virus containing either eGFP or 
MOG.  
To show the functionality of the retrovirally transferred cDNA library, we infected mouse cells 
with the human brain cDNA library and tried to detect by FACS MOG expression using the 
same antibody as in previously performed control experiments (Figure 21B). The FACS plot 
shows no differences for the control staining compared to the MOG specific staining. 
According to these experiments and other assays we were not able to show cDNA library 
expression in mammalian cells. Because of these difficulties and the high effort to construct 
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Figure 21. FACS analysis for the verification of retroviral constructs. 
A: In this analysis two constructs have been verified for their functionality. eGFP and MOG was recombined 
into the retroviral expression vector pQCXIP. eGFP expression was visualized by direct FACS analysis, MOG 
infected cells were stained using specific antibodies. 
B: These two FACS panels represent the experiment with the goal to identify MOG expressing mouse cells, 







DM, IBM, and PM are distinguishable syndromes in the group of IMs. DM is thought to be 
primarily an antibody-mediated autoimmune disease, in which antibodies recognizing 
endothelial antigens activate the complement cascade (Dalakas and Hohlfeld, 2003). This 
activation could lead to a destruction of intrafascicular capillaries and subsequently to 
perifascicular myofiber atrophy induced by ischemia. However, the presence of such 
autoantibodies has never been proven. 
IBM and PM are thought to be T-cell mediated. Cytotoxic T cells surround and also invade 
the muscle fiber, expressing cytotoxic molecules, such as granulysin, perforin, and granzyme 
A (Goebels et al., 1996; Ikezoe et al., 2006; Orimo S et al., 1994). In IBM, a degenerative 
process of muscle fiber injury is also present. 
However, the immune mechanisms leading to the pathologies in IM are still controversially 
discussed. Recent publications from Greenberg et. al. (in which new technologies have been 
applied to study IM) have led to the discovery of new cell types and factors, which seem to 
be involved in these diseases. 
4.1 Inflammatory myopathies  
4.1.1 Dermatomyositis 
 
Histological analyses of several cases of dermatomyositis have shown the presence of B- and 
PCs, which is in line with common concepts, but recently plasmacytoid dendritic cell (pDC) 
infiltration as well. The presence of these main producers of type I interferons (pDC) induces 
the expression of IFN-α/β dependent genes like myxovirus resistance A (MxA), STAT-1 and 
MHC-1 in capillaries and perifascicular fibers (Nagaraju et al., 2005; Gallardo E et al., 2001; 
Greenberg et al., 2005b). The type I interferon production of pDC might be induced by 
immune complexes (consisting of antibodies against RNA or DNA and its antigen) which are 
binding to Fc receptors on the pDC and activate intracellular signaling cascades after 
internalization via toll like receptor 7 and 9.  
PDCs present antigens to T helper or T regulatory cells and can induce the differentiation of 
B cells into PCs (Boonstra et al., 2003; Nestle et al., 2005; Jego G et al., 2005). One other 
possibility is that a viral infection triggers IFN-α/β production. However, a viral infection has 
never been observed in IM (Dalakas, 2006b; Jongen et al., 1993; Leff et al., 1992).  
The production of IFN-α/β might have several consequences. Other cell types of the innate 
immune system, such as myeloid dendritic cells, monocytes, and pDCs, are activated by 
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interferons. B cells are induced to produce more anti-DNA antibodies. A further hypothesis is 
that IFN-α/β might contribute to muscle and endothelial cell injury. 
This concept suggests a strong interaction between the adaptive and innate immune system 
as observed in established autoimmune diseases, such as systemic lupus erythomatosus.     
  
However, further questions have to be answered addressing the identity of the target 
antigens. In this context an endothelial or nucleic acid antigen would indicate an 
autoimmune process, whereas a viral antigen would neglect autoimmune mechanisms 
involved in the pathogenesis of dermatomyositis.  
The presence of an IFN-α/β gradient with peak concentration in perifascicular (pf) areas and 
capillaries does not explain why capillaries within the whole fascicle are damaged. The 
mechanism underlying why pf myofibers upregulate IFN-α/β induced genes and are affected 
is still unknown (Hohlfeld and Dornmair, 2007). 
 
4.1.2 Inclusion-body myositis and polymyositis 
 
First histological analyses have been done to characterize the T-cell infiltrate for all T cells, 
cytotoxic and suppressor T–cells and helper T-cells (Arahata and Engel, 1984; Engel and 
Arahata, 1984; Arahata and Engel, 1986). These studies done in the 1980s have some 
limitations in view of our current knowledge of T-cell biology. The antibodies used to stain all 
T cells were specific for the β-chain of CD8 T-cell receptors, and the staining therefore only 
revealed all CD8+ T-cells. The antibody for CD4+ helper T-cells also stains macrophages and 
dendritic cells because they express the CD4 receptor as well. These restrictions led to 
wrong calculations of the number of all cells and helper T-cells.  
The analysis of the T-cell receptor repertoire in IBM and PM by spectratyping, laser 
microdissection and sc-PCR of the TCR transcripts has demonstrated the presence of a 
clonally restricted populations of T cells in IBM and PM muscle (Hofbauer et al., 2003; Fyhr 
et al., 1997). Microarray analyses have shown that Ig transcripts are highly expressed in IBM 
and PM (Greenberg et al., 2005a). Histological analyses for PCs verified their presence in 
muscle tissue as the main producers of Igs. These sequences show all features which 
characterize affinity maturation by a GC reaction.  
A further recent finding was the identification of myeloid dendritic cells (mDCs), surrounding 
and invading non-necrotic muscle fibers (Greenberg et al., 2007). mDCs are professional 
antigen-presenting cells and might, therefore, contribute to the pathogenesis in IBM and PM, 
by forming immunological synapses with T cells and also B cells.  
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The question, which trigger initiates the inflammation of the muscle remains unsolved. What 
are the antigens of the expanded PCs and T cells? Do they target the same antigen by linked 
recognition? Are cells present in the muscle, which are necessary for an ectopic germinal 
center reaction in the muscle such as FDCs?  
 
Bradshaw et al. recently described the presence of B- and PCs in IM. They characterized the 
Ig repertoire by creating a hc Ig cDNA library from isolated RNA from whole tissue sections 
and showed the presence of clonally expanded B and PCs and Ig sequences with features of 
a GC reaction. 
However, that study has some limitations. First of all, by cloning total RNA (isolated from 
muscle biopsies) it was impossible for them to distinguish between Ig produced by B cells or 
by PCs. Furthermore, detection of clonal expansions is difficult due to technical limitations. 
Expansions are only detectable by cloning Ig cDNA from different areas of the same section. 
Additionally, it is not possible to determine whether the B cells originate from the tissue or 
from blood vessels.  
 
The objective of this study was a detailed analysis of the PC repertoire in inflammatory 
myopathies. Several biopsies from IBM, DM, and PM patients containing PC infiltrates were 
analysed using two independent approaches: For the analysis of the overall clonal 
composition of the B- and PCs contained in individual biopsies, we determined the CDR3 
length distribution of Ig hc transcripts by CDR3 spectratyping. For the more detailed analysis 
of the hc and lc Ig sequence of individual tissue-infiltrating PCs, we applied a combination of 


















4.2 Results from IM repertoire analyses 
 
In our study we analyzed the PC repertoire in five biopsy samples of IBM, four of DM, and 
two of PM. All cases were clearly diagnosed diseases and were verified by a histopathologist. 
In one analyzed IBM biopsy we observed a prominent PC infiltrate with Ig genes of IgG 
isotype. After analyzing eighty sequences, we had clear evidence of clonal expansions of at 
least eight clones. These clones were found in separate experiments, and two of them were 
verified by CDR3 spectratyping. Except in one clone, all sequences were identical in their 
nucleotide sequence, containing a moderate to high number of somatic hypermutations, 
which characterizes affinity maturation. The finding of higher R/S ratios in the CDR regions 
of expanded clones compared to lower ratios in the CDR regions of non-expanded clones 
provides further evidence for this phenomenon. Additionally we found strongly expanded PCs 
in two IBM biopsies containing replacement mutations, but no clonal variation.  
Analyses of PCs infiltrating muscle tissue of DM and PM patients indicate a polyclonal PC 
repertoire with weak clonal expansions, but more cases of clonal variation (7) than that 
found in IBM (3).  
Our data is in line with the results shown in the publication of Bradshaw et al. However, our 
study verifies the findings of Bradshaw et al. in a more detailed and definite way by 
analyzing not only Ig expression from tissue, but also the PC infiltrate, in particular. Our 
approach allows, on the one hand, a detailed analysis of both heavy- and light-chain Ig of 
single PCs and, on the other hand, provides information of the PC location in the biopsy. It 
also indicates clonal expansions in a more direct way, in terms of comparing each hc 
sequence from individually isolated PCs of independent experiments. Furthermore, the 
amplification of heavy- and light- chain Ig from the same cell allows the recombinant 
expression of the antibody and the possible identification of the cognate antigen. 
The finding of clonal expansions of PCs in IM is in line with the presence of CD8+ T-cell 
expansions (Hofbauer et al., 2003). This indicates that a targeted immune response is 










4.3 Using LM for the analysis of single immune cells 
 
The laser-microdissection technique was developed in the mid-1990s at the National Institute 
of Health by Emmert-Buck and colleagues. (Emmert-Buck et al., 1996; Simone et al., 1998). 
It was first used in the isolation of tumor tissue. This technique was further improved over 
the last decade. 
Laser microdissection in cellular immunology of human diseases is a very suitable technique 
to dissect single cells from complex tissues. Tissues (and especially diseased tissues such as 
tumors) are complex three-dimensional structures, which contain highly heterogeneous cells 
concerning phenotype and morphology. In combination with highly specific 
immunohistochemical staining procedures, a pure cell population can be isolated. In contrast 
to fluorescence activated cell sorting (FACS) from previously digested tissue, the information 
of cellular environment of the target cell type is maintained in LM. Furthermore, LM allows 
the analysis of RNA, DNA or protein for the detection of gene expression with real-time PCR 
or Western blotting, or the accumulation of cells for the purpose of mRNA microarrays 
(Curran et al., 2000). 
In our study we were interested in the B-cell response in inflammatory myopathies. The 
necessary techniques (fast and efficient staining, the isolation of small tissue pieces 
containing the cell of interest and the amplification of Ig hc and lc genes) had to be 
established. 
Since there are RNA-degrading enzymes not only in the tissue itself but also in labware and 
buffers, all of these methods required preservation of the RNA integrity. For this reason, all 
chemicals were of highest available purity. Solutions, which were in contact with the tissue 
or cell lysate, contained a potent RNase inhibitor.  
PCs as target cells have the advantage that they contain 10-20% mRNA of total mRNA 
coding for the Ig genes, making amplification more efficient. Because of the high 
amplification power of our PCR, we had to avoid the generation of PCR products from 
contaminating agents (such as previously cloned PCR products). For this reason, we 
performed the LM, sc RT-PCR and product purification in different rooms. We always 
compared newly generated products with sequences we already obtained from other 
biopsies and never observed any cross-contamination. 
Some LM samples were comprised by more than one PC, since we could amplify both Ig hc 
genes of IgG and IgM isotype. The fact that we amplified the same sequence in different 
independent LM experiments shows the reproducibility of our method. In these experiments, 
we observed the correct pairing of the hc to the lc, as well. Additionally, we verified three 
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expanded sequences by a completely different method. We used CDR3 spectratyping to 
initially detect clonal expansion and identify the corresponding Ig sequence of the expanded 
clone. Thus, we showed that the generated sequences from LM experiments were no 
artifacts, instead, the intrinsic products of the infiltrating PCs.  
The sequence repertoire analysis, including several hundreds of Ig hc sequences, gives 
inside into the PC situation being present at one time in the course of the disease. It neither 
gives information about time-dependent changes, concerning the repertoire of Ig gene 
transcripts in the early phase of the humoral immune response, nor about the impact of 
treatment with immunomodulating drugs or possible antigen spreading events. To meet the 
technical limitations of LM and sc RT-PCR a second, broader approach, namely CDR3 

























4.4 Occurrence of expanded plasma cells in IM tissue 
 
We assume that the B-cell precursors of the expanded clones matured and increased their 
affinity in the muscle tissue. The presence of clonally expanded PCs with features of affinity 
maturation implies an antigen-driven immune response in the target tissue. The clonal 
variation, which we observed in some of the analyzed biopsies, further supports affinity 
maturation by a GC reaction inside or outside the inflamed tissue. By comparing the 
mutations between similar sequences, a genealogy has been established. It seems very 
unlikely that the expanded PC clones migrate into the inflamed tissue by chance, since 
mechanisms in which antigen-specific cells are recruited by chemokines into sites of antigen 
persistence are not described. This assumption is verified by the fact, that infiltration by PCs 
is not a general feature of IM even in cases where a strong infiltrate is present but contains 
no PCs. Additionally, PCs need specific survival factors and attractant molecules to migrate 
into inflamed sites. However, we cannot completely exclude that PCs are unspecifically 
recruited to the inflamed muscle by such factors, but this seems unlikely since PC infiltration 
is not a general feature of IM. 
4.5 Do plasma cells play a role in disease pathogenesis? 
 
GC-experienced plasmablasts home to the bone marrow by CXCR4–CXCL12 interaction, 
where they differentiate into PCs and receive survival signals (Hauser et al., 2002). These 
signals keep the PCs alive by inducing an unfolded protein response. Otherwise, the cell 
would undergo apoptosis due to endoplasmic reticulum stress, which is generated by high 
antibody production (Iwakoshi et al., 2003). At this location, the PCs fulfill the function of 
maintaining protective antibody serum levels and immunological memory.  
Under inflammatory conditions, chemoattractants (addressing PCs) are produced in inflamed 
tissues induced by IFN-γ. These ligands which are CXCL9-11 bind to CXCR3 on PCs and 
direct them to the site of inflammation (Muehlinghaus et al., 2005; Baggiolini, 1998; Manz et 
al., 2002; Hauser et al., 2002).  
These antibody-secreting cells are also detected in chronically inflamed tissues (Cassese et 
al., 2003; Mallison, III et al., 1988). As an example for the presence of autoantibodies in 
sites of inflammation, is e.g. systemic lupus erythomatosus (SLE) (Hutloff et al., 2004), in 
which also autoantibodies to intracellular antigens are observed as well in rheumatoid 
arthritis (RA) (Tsubaki et al., 2005; Schroder et al., 1996). The presence of PCs might have 
two functions. Either antigen-specific cells are located in the inflamed tissue to produce high 
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amounts of antibodies which bind to pathogens (beneficial), or the antibodies are directed 
against autoantigens, which would contribute to a more devastating disease pathogenesis. 
At these sites, PCs acquire survival factors as well as in the bone marrow, such as CXCL12, 
IL-6, BAFF and/or APRIL and TNF. These findings however do not explain the occurrence of 
autoantibodies in these diseases. (Hirano and Kishimoto, 1989; Schneider, 2005; O'Connor et 
al., 2004; MacLennan and Vinuesa, 2002; Hauser et al., 2002). 
We assume, according to comparisons of the expanded clones, that we analyzed the PC Ig 
repertoire after completing the GC reaction, since such a reaction leads to clonal variation of 
the B-cell receptor, but as a consequence only the clones with the highest affinity for its 
antigens survive. However, we cannot exclude an alternative pathway of affinity maturation 
outside the GC, which has also been demonstrated (William et al., 2002). 
Furthermore, a plasmacytoma, which would explain the presence of PCs in inflamed tissues 
but without any correlation to the immune response in IM, can be excluded according to the 
clinical history of the patients. It is tempting to speculate, that these antibodies produced by 
expanded PCs are specific for a muscle autoantigen or for an unknown pathogen. 
A recent finding published by Serafini et al. shows a dysregulated Epstein-Barr virus infection 
in B- and PCs in the brain of MS patients (Serafini et al., 2007).  
Epstein-Barr virus (EBV), a human herpes virus, latently infects B-lymphocytes and can also 
cause infectious mononucleosis. Infected B cells and PCs are found in ectopic lymphoid 
follicles in the meninges of MS-patients. The authors have shown that EBV-infected B cells 
are the target of CD8+ cytotoxic T-cells, and that the pathological symptoms in MS might be 
caused as a secondary effect of the immune response against the EBV-infected cells. We 
hypothesize that EBV might play a role in IM by infecting B cells, driving them into clonal 
expansion and further differentiation into memory B-cells and PCs (Kuppers, 2003). The 
cells, therefore, might undergo an unspecific GC reaction and would not necessarily play a 
directly disease-related role in the cause of muscle destruction in terms of being specific for 
a muscle or autoantigen (Brauninger et al., 2003). On the other hand it could possibly be an 
autoreactive B cells, specific for a muscle autoantigen and escaping tolerance mechanisms 







4.6 Long-lived plasma cells and immunopathology 
 
The generation of autoantibodies is a general finding in autoimmune diseases. Examples of 
classical autoimmune diseases are Hashimoto´s thyroiditis (Chiovato et al., 2003), 
antiphospholipid syndrome (de Groot and Derksen, 2005), myasthenia gravis (Hughes et al., 
2004) and bullous skin diseases (Amagai, 1999). These antibodies can be used as a 
diagnostic marker (Martin and Chan, 2004; Lipsky, 2001; von Muhlen and Tan, 1995). 
 
In SLE, autoantibodies against intracellular antigens are present and form immune 
complexes, activate complement and bind to Fc receptors (Martin and Chan, 2004). The 
defective clearance of apoptotic material might contribute to disease severity (Carroll, 2004). 
These antibodies also show features of somatic hypermutations and class switch 
recombination which suggests a T-cell-dependent activation (Shlomchik et al., 1990; Brard et 
al., 1999). The serum concentrations of antibodies are stable for special autoantigens but 
fluctuate for other autoantigens during the course of the disease. One explanation could be 
that stable serum concentrations are produced by long-lived PCs and the fluctuating 
concentrations by short-lived PCs or plasmablasts. This is underlined by the presence of 
plasmablasts in the blood, with highly mutated Ig genes (Jacobi et al., 2003; Odendahl et 
al., 2000). The presence of autoantibodies is well-known for IM, especially for DM where 
20% of patients have antibodies against nuclear and cytoplasmic antigens, associated with 
protein synthesis and translational transport (Targoff, 2002).  
Autoantibodies are assumed to cause depletion of capillaries in DM, activating complement 
on endothelial cells. This immune reaction would explain perifascicular myofiber atrophy. 
Further research, using recombinant antibodies derived from DM tissue, might finally proof 












4.7 Identification of target antigens by expression cloning 
 
Since the characterization of the hc and lc Ig gene repertoire indicates the presence of an 
antigen-driven immune response in IM, the identification of the cognate target antigens 
would give insight into the factors which trigger the diseases. Therefore, the establishment 
of a system which would identify such antigens in IMs and also other neurological diseases 
e.g. MS would potentially contribute to our final goal of investigation.  
This system should resemble as much as technically possible the native protein antigens and 
additionally be highly specific and allow a rapid identification. The most suitable system in 
our opinion would be a eukaryotic expression system including all posttranslational 
modifications. Additionally, viral-mediated gene transfer should allow a good control over the 
number of genome-integrated transgenes per cell and should contribute to a simple 
identification of the integrated provirus, as well.  
In the beginning of our study, much effort has been spent on the construction of retrovirally 
mediated cDNA libraries from muscle and brain material. Many factors have contributed to 
the decision to give up this part of the project. Some of them are discussed below. 
 
4.7.1 Limitations of the approach 
 
a) Reduced antigen display 
Antibodies usually recognize linear epitopes or conformational epitopes. Both groups of 
epitopes can be produced using the mammalian-library approach. If the epitope, however, is 
generated by proteins which build heterodimers or higher order of complex formation, the 
epitope cannot be mimicked by our system, because only one particular protein is expressed 
by one infected cell. 
 
b) Lacking normalization 
The transcription of genes is dependent on the cell type and directly regulated by promoter 
activation. The quantity of different mRNAs can vary between five up to thousands of mRNA 
copies of one gene, so it is very likely, when the antibody is recognizing a low expressed 
protein, that it is only very little represented in the recombinant library. The cDNA library is 
further contaminated by highly expressed transcripts, e.g. housekeeping genes of the cell. In 
a normalized library the transcripts are represented more equally, because highly abundant 




c) Truncated cDNAs 
The quality of the library is dependent on several different factors. One very important 
criterion is the quality of the RNA which is used for reverse transcription and also the reverse 
transcription reaction. In both cases, a bad quality or suboptimal reaction conditions might 
lead to the generation of cDNA fragments, which do not contain the whole coding sequence. 
The resulting polypeptide chains are not complete or the translation will be out of frame, 
when an alternative start codon is used. 
 
d) Infection and toxic inserts 
In our experiments it was very difficult to measure the viral titer of the library virus. We 
always transfected and infected the same plasmid containing eGFP in a parallel experiment. 
This allowed us to get a first hint on the transfection efficacy of the packaging cell line and of 
the viral titer of the eGFP virus. However, these findings cannot be directly transferred to the 
library containing virus, because the viral titer is not only determined by the vector 
backbone, but also by the cDNA sequence length. Because of this, the viral titer should be 
calculated directly by selecting library infected cells with puromycin. This procedure is very 
time-consuming and often led to mistakes. As an alternative, we recombined the library into 
the same expression vector, which instead of a puromycin selection marker contains an IRES 

















4.8 Future research and application 
 
Our experimental approach allows the resurrection of the whole antibody molecule with the 
same antigen specificity as produced by the patient immune system, as we have obtained hc 
and lc Ig from one individual PC. With the antibodies from expanded clones in hands, it 
would be the final goal to identify the target (auto)antigen. This might help to explain the 
perifascicular myofiberatrophy in dermatomyositis and muscle fiber destruction in IBM and 
PM.  
If the target antigen is of pathophysiological significance, therapeutic approaches should 
target the B- and PCs. One monoclonal anti-CD20 antibody (Rituximab®) is already 
undergoing a clinical trial. However, it would only target CD20+ B cells but not PCs 
(Clinicaltrial.gov). Other approaches should target the pDC and mDC present in DM and IBM, 
to prevent secretion of IFN-α/β as well as antigen presentation. Since CD8+ T-cells are also 





Our study gives insight into the role PCs may play in the immunopathogenesis of IM. Our 
approach provides a detailed analysis of the PC repertoire by two independent methods that 
are CDR3 spectratyping and sc RT-PCR. According to strong clonal expansions of PCs with 
highly mutated Ig genes present most prominently in IBM biopsies, we have strong evidence 
for an antigen-driven immune response including affinity maturation. LM of single PCs 
provides both information of the location of cells and the sequence of heavy and light chain 
Ig genes. This approach allows further identification of the corresponding antigens by the 
resurrection of the original antibody specificity. Further research might reveal the target 
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6 Supplementary tables  
 
No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
DM-1  
(14/06)                       
1 070411 21  V3-15*01 96.45 D2-8*01 n.d. J5*02 80.43 C A T Q Y K T L   IgG 6 
2 070411 5 V3-15*01 94.81 D6-13*01 100.00 J5*02 75..61 C T G G K S G H W   IgM 7 
3 070321 4 V3-15*01  94.93 D4-17*01  71.42 J4*02  89.58 C A T E D Y G D L G Y W                   id  IgG 10 
4 070411 15 V3-15*01 94.74 D4-17*01 71.42 J4*02 89.58 C A T E D Y G D L G Y W                   id  IgG 10 
5 070411 22 V3-7*02 98.89 D1-14*01 62.50 J4*02 79.16 C A R E I K R G G D D W   IgM 10 
6 070321 1 V1-69*01  94.32 D3-16*01 80.00 J4*02  85.41 C A R D L G Q L S L Y F W   IgG 11 
7 070411 13 V3-74*02 93.33 D3-16*01 66.66 J4*02 97.91 C A R D R R G Y Y F D Y W   IgM 11 
8 070212 4 V1-2*02 94.12 D3-9*01  82.35 J4*02 89.58 C A R A D I L T G N N L D F W   IgM 13 
9 070212 24 V3-23*04  97.84 D4-17*01  53.33 J4*02 85.41 C T K D R P V T K R L F D Y W              di  IgM 13 
10 070212 26 V3-23*01  93.33 D1-1*01 66.66 J4*02  87.50 C T K D R P M T K R L F D N W              di  IgM 13 
11 070321 11 V3-23*04  94.81 D4-17*01  53.33 J4*02 87.50 C T K D R P V T K R L F D Y W              di  IgM 13 
12 070411 26 V4-39*01 97.29 D6-19*01 66.66 J4*02 85.41 C A R P R R G N G S G F D Y W              di  IgG 13 
13 070411 32 V4-39*01 97.46 D6-19*01 66.66 J5*01 82.35 C A R P R R G N S S G L D Y W              di  IgG 13 
14 070411 8 V3-64*05 86.38 D5-24*01 71.42 J5*01 74.50 C M I V G R D S N S L G Q A S W   IgG 14 
15 070411 16 V1-3*01 98.91 D2-15*01 85.00 J4*02 83.33 C A R G I C S G G S C P F A Y W   IgM 14 
16 070411 31 V3-30*01 97.19 D3-3*01 80.00 J5*02 80.39 C A R D R M S Y G D H G P G N W   IgM 14 
17 070212 2 V3-23*01  97.80 D6-13*01 58.82 J4*02 85.50 C A K D R R G S S K G L F F D Y W   IgM 15 
18 070212 7 V3-23*01 96.34 D3-22*01  78.94 J4*02 77.08 C A T Q K R Y F D S S G Y L G D W   IgM 15 
19 070212 21 V1-69*06 93.05 D1-26*01 77.77 J5*02 88.23 C V F S R G V G A T T Y W F D P W   IgM 15 
20 070321 8 V3-23*04  98.90 D4-11*01 56.25 J4*02  83.33 C A K D R I E P T T Y R G H D Y W   IgM 15 
21 070411 6 V3-33*03 88.15 D2-8*02 64.28 J5*02 86.27 C A R D G G N I I L V G W F D A W   IgG 15 
22 070411 9 V4-39*01 87.46 D5-24*01 58.82 J3*01 86.00 C A R H S L Y R L P Q S G A F D V W   IgG 16 
23 070411 19 V3-20*01 98.89 D6-19*01 85.71 J3*02 96.00 C V R G G Y S S G W R R N A F D I W   IgG 16 
24 070411 20o V1-3*01 89.13 D3-9*01  72.72 J6*03 87.09 C V R V Q Y F S D L G Y H Y M D V W   IgG 16 
25 070212 1 V3-23*01 98.53 D2-2*01  76.92 J4*02 85.41 C A K G A A I V L V P A A T P F D Y W   IgM 17 
26 070321 2 V3-73*01  100.00 D4-17*01  68.75 J6*03  88.70 C T R P Y G D H G G G Y Y Y Y M D V W   IgG 17 
27 070411 7 V7-4-1*02 95.93 D5-18*01 55.00 J5*02 94.11 C A R G R R I D V S I Q K A W F D P W   IgG 17 
28 070411 2 V4-39*01 96.18 D3-3*01 75.00 J2*01 71.69 C A R R E R L L E W S S T W Y F D L W   IgM 17 
29 070212 10 V3-53*01 98.17 D3-10*01  72.41 J4*02 95.83 C A R E R R T M V Q G V N L Y Y F D Y W   IgM 18 
86 
 
30 070212 14 V3-64*05  97.04 D6-19*01  65.00 J3*02 86.00 C A K V S P R R T T V A V T G A F D I W   IgM 18 
31 070321 14 V3-53*01 94.01 D6-13*01  92.30 J6*03  82.25 C A R D R G I A A S G Q S Y Y Y M D V W   IgM 18 
32 070411 18 V3-53*01 96.74 D3-10*01 69.23 J6*03 80.64 C A R D R S A Y G S G S H Y Y Y M D A W   IgM 18 
33 070411 20 V3-53*01 96.74 D6-19*01 100.00 J6*03 87.09 C A R V K G I A V A G Q N Y Y Y M D V W   IgM 18 
34 070411 29 V3-53*01 95.13 D3-10*01 57.69 J5*02 86.27 C A R D R R V L F Q G V T S R W F D P W   IgM 18 
35 070411 32 V3-53*01 97.46 D3-10*01 64.28 J6*03 75.80 C A R D R A T M F Q G L T F R Y M D V W   IgM 18 
36 070321 11 V1-8*01  88.89 D2-2*01  56.66 J3*01  92.00 C A T R P S K Y Q M L S P T S D A F D L W   IgG 19 
37 070411 19 V3-23*04 93.68 D3-3*01 51.61 J3*02 86.00 C A K D R V R F L E W A T T X D A V D I W  di  IgM 19 



























No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
DM-2  
(354/03)                       
1 070105 28 V3-30*03 92.11 D6-13*01 72.73 J4*02  83.33 C A K A P A D P V G S W   IgG 10 
2 070129 2 V3-33*01 85.88 D1-1*01  83.33 J4*02 82.93 C A R D F R T G M T D Y W  IgG 11 
3 070129 35 V4-59*01 87.04 D5-24*01 80.00 J2*01 70.59 C A R E A I R R F F D L W  IgM 11 
6 070105 13u V1-3*01 95.12 D5-18*01 63.64 J4*02 79.17 C A R V Y G G L P  F D Y W   IgM 11 
4 070129 29 V3-73*01  95.79 D5-12*01 76.92 J4*02 87.50 C T S G Y D Q T Y F D Y W   IgM 11 
5 061215 21 V1-69*01 94.04 D3-16*01 61.53 J4*02 72.91 C A R A D Y E S G L V E D W   IgM 12 
7 070129 26 V1-69*01  92.01 D4-17*01 100.00 J4*02  85.42 C T R G D Y A E G L D D Y W   IgM 12 
8 070129 9 V4-b*01  92.91 D5-12*01 75.00 J5*02  90.91 C V R S R D Y L S W F V P W   IgG 12 
9 061215 14 V3-48*03  92.67 D4-17*01 81.81 J2*01 96.22 C A R E A Y G E N W Y F D L W   IgG 13 
10 070105 8 V1-69*01 90.76 D6-6*01  70.59 J4*02 83.78 C T R G M E Q L A S Y I G Y W  IgM 13 
11 070105 18 V3-74*02 93.33 D6-6*01  53.85 J5*02  80.39 C A R G S R P P S C P V D P W   IgM 13 
12 070105 24 V3-73*01 89.55 D1-1*01  60.00 J3*02  72.00 C L I V T D T F L D A F H I W   IgM 13 
13 070129 27 V4-30-4*01 91.37 D5-12*01 70.00 J4*02 90.24 C A R R L Q W L T D G F D Y W  IgG 13 
14 070105 39 V3-23*04 89.82 D1-1*01  72.73 J4*02  82.50 C A K D L A G L R S G F D F W                    di  IgM 13 
15 070129 15 V3-23*04 91.40 D3-9*01  66.67 J4*02  83.33 C A K D L A G L R S G F D F W                    di  IgM 13 
16 070105 34 V1-46*01 96.49 D6-19*01 75.00 J5*02  96.08 C A R E I E Q W V K N W F D L W   IgG 14 
17 070105 6 V3-30*03  96.53 D5-12*01 52.63 J4*02  77.08 C A K D R S Y W P L S H F D F W   IgM 14 
18 070105 17 V3-23*04 89.93 D4-17*01 66.67 J4*02  87.50 C A K D T T V T G R H Y F D N W   IgM 14 
19 070105 33 V3-74*02 91.85 D2-15*01 73.68 J4*02  84.38 C A R P G G C S G G S C F D Y W   IgM 14 
20 070129 12 V5-a*01 94.74 D6-19*01 61.90 J4*02 87.50 C A R R S C S G S S C F F D Y W   IgM 14 
21 061215 19 V3-64*05 92.22 D6-19*01 62.50 J1*01  75.00 C V T G P R Q W L V P H F H H W                  id  IgM 14 
22 070129 33 V3-64*05 83.33 D6-19*01 62.50 J1*01  75,00 C V T G P R Q W L V P H F H H W                  id  IgM 14 
23 061215 17 V4-4*07 87.41 D5-12*01 60.00 J4*02  89.58 C A R G I K R G R L Y Y F D F W                  di  IgG 14 
24 070129 8 V4-4*07 87.32 D5-12*01 60.00 J4*02  90.24 C A R G I K R G R L Y Y F D F W                  di  IgG 14 
25 061215 18 V3-15*01 90.78 D3-3*01  68.42 J5*02 76.47 C T T D L V F G V P M G W F D P W                id  IgM 15 
26 070105 12 V3-15*01 91.49 D3-3*01  68.42 J5*02 76,47 C T T D L V F G V P M G W F D P W                id  IgM 15 
27 070105 15 V4-59*02 92.67 D3-3*01  78.26 J4*02  81.25 C A R S A T A F G V V I H F D Y W   IgM 15 
28 070129 30 V3-64*05 94.07 D2-21*01 55.56 J4*02 91.67 C V K E R V N G P S R Y Y F D C W   IgM 15 
29 070129 3 V3-20*01 95.24 D5-24*01 70.00 J6*03 87.10 C A R P E F R K D Y H Y Y M D V W   IgG 15 
30 070105 5 V3-21*01  95.56 D6-13*01 58.82 J5*02 92.16 C V R E L E H L T L G G D W F D P W   IgG 16 
31 070105 17 V1-46*01  85.66 D3-10*01 56.52 J4*02  85.42 C V R G G S T L D E T D S F G G Y W   IgG 16 
88 
 
32 070105 27 V6-1*01  91.67 D6-19*01 84.21 J3*02 98.00 C T R T G V D S S G W F D A F D I W   IgG 16 
33 070105 35 V3-23*04 89.61 D2-21*02 75.00 J1*01 80.77 C V R D L R R G S C G G D C P P G W   IgG 16 
34 061215 16 V3-23*04  91.23 D3-22*01 89.47 J5*02 94.11 C A K G F T Y Y Y D S S E D W F D P W   IgG 17 
35 070105 25 V3-49*03 95.79 D6-13*01 100.00 J6*02 80.65 C T R D S S S W S S K G L K G M D V W   IgG 17 
36 070105 7 V3-23*04 93.90 D5-24*01 75.00 J4*02  87.50 C A K P S R Y G S G E K P Y Y F D Y W   IgM 17 
37 070105 29 V1-18*01  92.36 D2-15*01 55.56 J4*02  81.58 C A R D S S W E V P A K S L L V D F W   IgM 17 
38 070105 37 V3-23*04 97.78 D5-12*01 69.57 J4*02 90.00 C A K D N L D F L A T I P P N F D Y W   IgM 17 
39 061215 20 V1-69*06 88.77 D3-10*01 61.53 J3*01  74.00 C A V E S N Y I N S G S P L L A L D V W   IgM 18 
40 070105 43 V1-69*06 94.04 D3-10*01 69.23 J3*01  70.59 C G L E S N Y F G S G I P L L A L D V W  IgM 18 
41 070105 36 V3-53*01 88.65 D3-3*01  65.38 J4*02  85.42 C T R E R R L S V S G V T N A L F D R W   IgM 18 
42 070129 10 V3-7*02 96.34 D6-6*01  88.89 J4*02  83.33 C A R D Q P R I A A R P P R P Y F D N W   IgM 18 
43 070129 16 V1-69*06 92.47 D3-10*01 65.38 J3*01  76.00 C A L E S D Y F G S R S P L L A L D V W   IgM 18 
44 070129 18 V3-74*02 91.47 D4-23*01 57.89 J4*02  96.88 C A R S A A L R G Q L V P T Y Y F D H W   IgM 18 
45 070129 32 V4-39*01  97.13 D6-13*01 76.19 J2*01  77.36 C A S H R G M A A A D I V Y W Y F D L W   IgM 18 
46 070129 5 V3-30*05 91.67 D6-13*01 90.48 J2*01 84.91 C A R E A G H S S S W S P G R Y F D L W   IgG 18 
47 070129 24 V4-61*02 95.83 D3-3*01  86.21 J4*02  95.12 C A R T G I T L F G V V I E A Y F D Y W   IgG 18 
48 070105 2 V3-74*02 94.74 D3-3*01  85.19 J2*01 95.12 C A R D R I P I F G V V I P L W Y F D L W  IgM 19 
49 070105 42 V2-5*10  98.26 D3-10*01 88.46 J5*02 90.20 C T Q R P P I T M I Q G V I G N W F D P W   IgM 19 
50 070105 19 V3-23*01 87.37 D2-15*01 81.25 J6*03  91.94 C A R S L R D C S G G A C Y Y Y Y M D V W   IgG 19 
51 070129 11 V4-31*02 87.02 D3-3*01  74.19 J4*02  83.33 C A R G G V T V F G V V I N P F H F D T W   IgM 19 
52 070129 31 V3-23*04  92.63 D3-10*02 66.67 J4*02  95.83 C S K A P T I V F G D L L F I N Y F D Y W   IgM 19 
53 061215 15 V1-2*02 90.88 D3-3*01  75.86 J3*02 86.00 C A R G N P T S G F W T A Y Y P G T F D I W   IgG 20 
54 070105 14 V4-30-2*01 94.79 D2-2*01  77.42 J3*02 94.87 C A R A P D I V V V P V A I M G G A F D I W   IgM 20 
55 070129 6 V1-69*06 92.96 D3-22*01 56.00 J4*02  87.50 C A R D L N R R F P F D R A G W G P F D F W   IgG 20 
56 070129 19 V4-4*07 95.13 D6-19*01 84.21 J6*02 84.91 C A R G G G R I T V A G K L L S H Y G M D V W   IgM 21 
57 070129 14 V1-69*06  91.29 D2-21*02 80.00 J6*02  88.71 C S R D S Y C G A D C H L D Y F Y Y G M D V W   IgG 21 
58 061215 22 V4-61*01  91.67 D3-10*01 65.00 J6*03 82.25 C A G V R V E A T L V Q G V V L Y Y Y Y M D V W   IgM 22 
59 070105 36* V3-23*04 94.98 D3-10*01 76.92 J4*02  87.50 C A K T M V R G V I G G S G E R L T N Y F D H W   di  IgM 22 
60 070105 13 V3-23*04 98.96 D3-10*01 76.92 J4*02  87.50 C A K T M V R G V I G G S G E R L T N Y F D C W   di  IgM 22 
61 070129 34 V3-23*04 97.49 D3-10*01 76.92 J4*02  93.75 C A K T M V R G V I G G S G E R L T H Y F D Y W   di  IgM 22 







No   Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
DM-3 
(289/95)                       
1 070319 9 V4-34*01  95.08 D3-16*01  83.33 J5*02  70.58 C A R L G V T A I S L W                            id  IgM 10 
2 070319 28 V4-34*01  95.79 D3-16*01  83.33 J5*02  69.77 C A R L G V T A I S L W                            id  IgM 10 
3 070319 17 V5-51*01  96.67 D3-10*01 100.00 J2*01  96.22 C A R H P N W Y F D L W   IgG 10 
4 070314 3 V3-11*03  91.38 D5-18*01  70.00 J3*02  90.00 C A R A M A S D A F D M W   IgG 11 
5 070319 24 V1-18*01  98.52 D4-11*01 57.14 J5*02  94.11 C A R T L S N R W F D P W   IgG 11 
6 070319 25 V1-3*01  90.68 D5-12*01  69.23 J4*02  79.16 C T R G M L A Q L F E F W   IgG 11 
7 070314 21 V3-30*02  88.93 D2-21*01  62.50 J4*02  91.66 C A K D G G N G W Y Y F D Y W   IgG 13 
8 070319 22 V1-69*01  90.48 D3-22*01  58.82 J4*03  83.33 C A R A P M K V G G Y Y G A W   IgG 13 
9 070319 35 V4-59*01  87.12 D3-10*01  100.00 J6*02  75.80 C A R S E A A T P Y G L D V W   IgG 13 
10 070314 10 V1-18*01  83.33 D2-2*01  57.14 J5*02  84.31 C V T S R G A W P R D W F E A W   IgG 14 
11 070314 19 V3-64*05  96.13 D2-15*01  66.67 J3*01  88.37 C V R L Y V V V G V G A F D L W  IgM 14 
12 070319 10 V4-59*01  87.41 D3-3*02  66.66 J6*02  72.58 C A R Q P F W S G Y L Y G L D V W   IgG 15 
13 070319 12 V5-51*01  95.57 D5-24*01  100.00 J4*02  93.75 C A R H R S R R D G Y N S F D Y W   IgG 15 
14 070319 31 V3-23*01  90.84 D2-15*01  77.27 J4*02  87.50 C A K G K F C S G G N C L S D Y W   IgG 15 
15 070319 13 V3-33*01  98.90 D3-22*01  70.00 J2*01  88.67 C A R D S S S D N S C P G Y F D V W   IgG 16 
16 070314 5 V4-39*01  99.28 D6-19*01  86.66 J3*02  96.00 C A R Q A V A G I Y L S P G A F D I W   IgG 17 
17 070314 6 V4-4*02  93.40 D3-10*02  52.38 J4*02  93.75 C A R G S T Q L V W S S I I Y F D Y W   IgG 17 
18 070314 9 V3-21*01  86.74 D3-22*01  67.74 J4*02  79.16 C A R S Y Y H D P S G Y R R T P F E H W   IgG 18 
19 070314 17 V4-b*02  96.52 D3-22*01  100.00 J3*02  90.00 C A I S T Y Y Y D S S G Y L G A F D I W            id  IgM 18 
20 070319 12 V4-b*02  95.57 D3-22*01  100.00 J3*02  90.00 C A I S T Y Y Y D S S G Y L G A F D I W            id  IgM 18 
21 070319 21 V4-39*06  95.13 D3-16*02  60.00 J5*02  98.03 C A R D V L V I L P V G I K N W F D P W   IgG 18 
22 070319 6 V1-69*01  98.52 D3-22*01  96.29 J1*01  94.23 C A T C T Y Y Y D S S G Y Y L E Y F Q H W   IgG 19 
23 070319 9 V3-7*01  92.22 D1-26*01  55.55 J6*02  90.32 C A R D Y R V G G P W D Y D Y Y G L D V W   IgG 19 
24 070319 27 V5-a*01  95.56 D2-2*01  56.66 J5*02  86.27 C A R P S C S S N T C P T C S C K F Y P W   IgG 19 
25 070314 2 V5-51*01  91.11 D3-16*01  68.42 J6*02  88.70 C A R Q G G Y P N S R M V D Y Y Y G M D V W   IgM 20 
26 070314 13 V1-3*01  90.74 D6-13*01  66.66 J6*02  87.09 C V R G A V H S G S W E W G P K N R Y F Y A M D V W   IgG 24 








No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
DM-4 
(354/98)                      
1 070328 12 V3-7*01 89.61 D5-5*01 100.0 J3*02 84,00 C A R D L R V F D M W   IgG 9 
2 070328 16 V1-3*01 89.12 D6-19*01 75.00 J4*02 85.41 C A R G D R S S G F D S W   IgG 11 
3 070328 18 V1-2*02 97.49 D2-2*01 55.55 J4*02 87.50 C A R S Q S Q L A V D Y W   IgG 11 
4 070404 35 V1-18*01 90.74 D1-26*01 80.00 J4*02 85.41 C A R D G R D D G E D Y W   IgG 11 
5 070328 20 V1-46*01 93.48 D3-16*02 53.33 J4*02 85.41 C A R Q A V G V I P Y D Y W   IgG 12 
6 070404 1 V3-30*03 70.83 D6-6*01 53.33 J4*03 77.08 C A R A H N I P S P P D A W   IgG 12 
7 070328 10 V1-2*02 83.33 D2-8*01 63.63 J3*01 90.00 C A L T A G F Y R D A F D F W   IgG 13 
8 070404 9 V3-23*01 82.20 D3-3*01 64.28 J3*02 84.00 C A K D L W R H F N V F D S W   IgG 13 
9 070328 14 V4-34*01 64.88 D2-15*01 63.16 J4*02 87.80 C G E E L H G D G G A G F D Y W  IgG 14 
10 070328 2 V4-34*08 96.21 D6-13*01 80.00 J4*02 89.58 C A M K S G R R S S W S L D Y W   IgG 14 
11 070328 3 V1-2*02 90.06 D5-5*01 66.66 J3*02 92.00 C A R E G G G G N R D G L D M W   IgG 14 
12 070404 18 V3-30*09 90.37 D5-12*01 78.57 J4*02 91.66 C A R G F R G Y S G H D L D Y W   IgG 14 
13 070404 22 V3-30*03 84.44 D2-2*01 64.28 J4*02 81.25 C A R A R S F A V S S P P D A W   IgG 14 
14 070404 23 V3-30*03 88.26 D3-22*01 61.53 J4*02 70.83 C V Q S D S S G F Y L L G G Y W                    id  IgG 14 
15 070404 25 V3-30*03 88.26 D3-22*01 61.53 J4*02 70.83 C V Q S D S S G F Y L L G G Y W                    id  IgG 14 
16 070404 30 V1-2*02 88.04 D7-27*01 85.71 J4*02 83.33 C A R A G Q Q G I H P L I D Y W   IgG 14 
17 070328 21 V3-30*03 94.57 D1-26*01 54.55 J4*02 83.33 C A R D R L S R H K V P T I G Y W  IgG 15 
18 070328 23 V4-34*01 86.52 D3-9*01 62.96 J4*02 83.33 C A H T T V L T T S Y Q A W E F W   IgG 15 
19 070328 27 V3-7*02 74.00 D4-23*01 68.42 J4*02 87.50 C A R D G V G G Y S P R D F D S W  IgG 15 
20 070328 1 V2-70*01 85.72 D3-10*01 72.72 J4*02 87.50 C A R T P F Y F G M G S Y F F D Y W   IgG 16 
21 070404 24 V4-61*01 92.96 D3-9*01 85.71 J5*02 82.35 C A R A V L R D F D W L L G V D P W   IgG 16 
22 070404 29 V3-7*01 95.56 D4-23*01 70.00 J6*02 85.48 C A R V E T P P V P S Y Y G M D V W   IgG 16 
23 070328 11 V3-11*01 91.67 D3-22*01 100.00 J4*02 89.58 C A R G G L Y Y Y D S S G V P F D Y W   IgG 17 
24 070404 6 V4-59*01 93.94 D2-8*02 55.55 J4*02 75.00 C A R S H P K A V F D W S A C L D S W   IgG 17 
25 070404 19* V1-46*01 96.77 D3-10*02 61.53 J6*02 88.70 C A R D K C E T Q H Y Y Y Y A L D V W   IgG 17 
26 070404 32 V4-61*08 83.33 D4-17*01 75.00 J6*02 82.25 C A R V H D Y G A Y A G D Y K Y V M D V W   IgG 19 
27 070404 3 V3-30*03 95.93 D6-13*01 68.75 J6*02 85.48 C A K D S S K V V A A V N F W Y Y G M D V W        id  IgG 20 
28 070404 4 V3-30*03 95.93 D6-13*01 68.75 J6*02 85.48 C A K D S S K V V A A V N F W Y Y G M D V W        id  IgG 20 
29 070404 31 V1-46*01 91.67 D3-10*01 66.66 J6*02 80.64 C A R D G T H L L G V G E L Y S N G M D V W   IgG 20 
30 070328 17 V3-15*01 88.28 D2-8*01 61.53 J3*01 88.00 C T T G P A S V G S C D T D N C P D A F N L W   IgG 21 
31 070328 30 V1-2*02 89.26 D3-9*01 77.41 J5*02 78.43 C A R E S R S N Y N I M T A Y Y K D P A E D H W   IgG 22 
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32 070404 15 V1-2*02 90.53 D6-13*01 61.90 J5*02 94.11 C A R R G R R S I T I G G S A P P D G W F D P W    id  IgG 22 
33 070404 16 V1-2*02 90.53 D6-13*01 61.90 J5*02 94.11 C A R R G R R S I T I G G S A P P D G W F D P W    id  IgG 22 
34 070328 4 V1-69*06 90.37 D3-9*01 58.06 J4*02 91.66 C A K V V P A R V L R H F D S A P N L L Y F D I W   IgG 23 
35 070328 7 V1-69*06 88.77 D3-3*01 65.38 J6*02 85.48 C A G R Q A S G I S V F G V G P S S Y F H Y P M D V W  IgG 25 






























No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
IBM-1 
(451/96)                      
1 061213 27 V3-11*01  93.18 D5-5*01  90.00 J4*02 85.41 C A K G Y Q Y A H Y W   IgG 9 
2 070510 14 V3-23*01 92.80 D4-17*01 60,66 J4*02 89.58 C A Q G D Y G P D Y W   IgG 9 
3 070521 37 V3-23*01 88.64 D2-21*02 80.00 J4*02 87.80 C A K G D Y G P D C W   IgG 9 
4 061206 15 V3-30*09 88.89 D4-4*01  100.00 J4*02 81.25 C V A D Y R S L G D Y W   IgG 10 
5 061221 27 V4-30-4*01 95.29 D6-6*01 71.42 J3*02 100.00 C A R I R D D A F D I W   IgG 10 
6 061206 17 V1-18*1  90.94 D6-19*01 83.33 J4*02  83.33 C A R Y T S A C P S C F W   IgG 11 
7 061206 19 V3-15*01 94.93 D3-22*01 71.42 J2*01 92.45 C T S Y E S S G W Y F D L W   IgG 12 
8 070116 16 V4-61*01  89.24 D4-23*01 n.d. J4*02  83.33 C A R D D Y A T N T V V D W   IgG 12 
9 061206 32 V3-15*07  92.91 D3-3*01  75.00 J4*02 83.33 C S T E R T F G V I L I R D W   IgG 13 
10 061213 37 V1-f*01 94.20 D6-6*01  58.33 J4*02 93.75 C A T E V G R S R S S F D Y W   IgG 13 
11 061221 28 V5-51*01 96.74 D1-7*01 100.00 J6*02  72.58 C A R Q L E L R R R G M D L W   IgG 13 
12 070116 41 V1-f*01  85,42 D1-1*01  87.50 J5*02  80.39 C G T G T N N W H G G I A H W   IgG 13 
13 061221 12 V6-1*01 96.77 D6-19*01 75.00 J6*02  80.64 C A R E H W L G H Y Y G M A V W   IgG 14 
14 070116 17 V1-3*01 93,19 D3-10*01 100.00 J4*02 93.75 C A S Y Y G S G S Y W F F D Y W   IgG 14 
15 061206 13 V1-18*01 88.51 D1-14*01 60.00 J4*02  93.75 C A R G K R G A R D N Y F D Y W                    id  IgG 14 
16 061213 23 V1-18*01 88.51 D1-14*01 60.00 J4*02  93.75 C A R G K R G A R D N Y F D Y W                    id  IgG 14 
17 070510 35 V1-18*01 88,51 D1-14*01 60.00 J4*02 93.75 C A R G K R G A R D N Y F D Y W                    id  IgG 14 
18 061221 15 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
19 061221 19 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
20 061221 20 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
21 061221 22 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
22 061221 23 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
23 061221 29 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
24 061221 31 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
25 070116 27 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
26 070116 28 V3-9*01 97.78 D4-17*01 90.00 J4*02 91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
27 070116 30 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
28 070116 40 V3-9*01 97.78 D4-17*01 90.00 J4*02 87.50 C V Q D T V T N L N Y S F A X W                    id  IgG 14 
29 070116 31 V3-9*01 97.78 D4-17*01 90.00 J4*02  91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
30 070510 2 V3-9*01 97.78 D4-17*01 90.00 J4*02 91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
31 070510 34 V3-9*01 97.78 D4-17*01 90.00 J4*02 91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
32 070510 37 V3-9*01 97.78 D4-17*01 90.00 J4*02 91.66 C V Q D T V T N L N Y S F A S W                    id  IgG 14 
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33 070116 18 V4-59*01 92.18 D3-22*01 77.27 J4*02  92.68 C A R T S Y H E S I G Y Y F D Y W   IgG 15 
34 070510 7 V3-23*04 93.94 D3-22*01 68.18 J4*02 93.75 C A A E R A Y G S S G Y A F D Y W   IgG 15 
35 061221 5 V3-33*02 n.d . D1-26*01 66.66 J3*02  92.00 C A R N S H G G R S S D A F D I R                  id  IgG 15 
36 070116 33 V3-33*02 69.23 D1-26*01 66.66 J3*02  92.00 C A R N S H G G R S S D A F D I R                  id  IgG 15 
37 070116 21 V3-33*01 87.64 D1-26*01 66.66 J3*02  92.00 C A R N S H G G R S S D A F D I R                  id  IgG 15 
38 061206 30 V4-30-4*01 86.31 D4-17*01 81.25 J5*01  86.27 C A R H L Y D Y G D F A K W L D S W   IgG 16 
39 070116 14 V3-13*01 94.01 D6-25*01 82.35 J2*01  88.67 C A R G R G I G A A E T R Y L D L W   IgG 16 
40 070510 30 V5-51*01 94.07 D1-26*01 n.d. J6*02 88.70 C A R F L L G D T Y Y Y Y G M D V W   IgG 16 
41 061221 4 V3-74*01 n.d.  D2-2*01  n.d. J4*02  91.66 C A R R G R L D S T S R F Y F D F W                id   IgG 16 
42 061221 11 V3-74*02 87.68 D2-2*01  n.d. J4*02  91.66 C A R R G R L D S T S R F Y F D F W                id  IgG 16 
43 070116 3 V3-74*02 87.68 D2-2*01  n.d. J4*02  91.66 C A R R G R L D S T S R F Y F D F W                id  IgG 16 
44 070116 23 V3-74*02 87.68 D2-2*01  n.d. J4*02  91.66 C A R R G R L D S T S R F Y F D F W                id  IgG 16 
45 061221 17 V3-23*04 86.08 D3-16*01 66.66 J4*02 89.58 C A K C G P F G G V M V I P F D Y W                id  IgG 16 
46 061221 33 V3-23*04 91.67 D3-16*01 66.66 J4*02 89.58 C A K C G P F G G V M V I P F D Y W                id  IgG 16 
47 070521 27 V3-23*01 88.00 D3-16*01 66.66 J4*02 89.58 C A K C G P F G G V M V I P F D Y W                id  IgG 16 
48 070510 13 V3-23*04 93.48 D3-16*01 66.66 J4*02 89.58 C A K C G P F G G V M V M P F D Y W                id  IgG 16 
49 070510 20 V3-33*01 94.12 D2-2*03 68.00 J4*02 82.93 C V R D G Y C T S A N C Y F F Q H W                id  IgG 16 
50 070510 48 V3-33*01 94.12 D2-2*03 68.00 J4*02 82.93 C V R D G Y C T S A N C Y F F Q H W                id  IgG 16 
51 070521 38 V3-33*01 94.12 D2-2*03 68.00 J4*02 82.93 C V R D G Y C T S A N C Y F F Q H W                id  IgG 16 
52 070521 39 V3-33*01 94.12 D2-2*03 68.00 J4*02 82.93 C V R D G Y C T S A N C Y F F Q H W                id  IgG 16 
53 070521 43 V3-33*01 94.12 D2-2*03 68.00 J4*02 82.93 C V R D G Y C T S A N C Y F F Q H W                id  IgG 16 
54 061206 22 V1-18*01  75.56 D3-22*01 72.72 J5*02  82.35 C G R D E S S S N K S R G R R L D P W              bs  IgG 17 
55 061206 24 V1-18*01 84.23 D3-22*01 72.72 J5*02 88.23 C A R D E S S S N K S R R R R F D P W              id  IgG 17 
56 061206 36 V1-18*01 84.23 D3-22*01 72.72 J5*02 88.23 C A R D E S S S N K S R R R R F D P W              id  IgG 17 
57 061213 24 V1-18*01 84.23 D3-22*01 72.72 J5*02 88.23 C A R D E S S S N K S R R R R F D P W              id  IgG 17 
58 061213 6 V1-18*01  84.23 D3-22*01 72.72 J5*02 88.23 C A R D E S S S N K S R R R R F D P W              id  IgG 17 
59 061213 29 V1-18*01  84.23 D3-22*01 72.72 J5*02 88.23 C A R D E S S S N K S R R R R F D P W              id  IgG 17 
60 061213 18 V1-18*01 n.d. D3-22*01 68.00 J5*02 88.23 C A R D E S S S N K S R R R R F D P W              id  IgG 17 
61 061206 7 V4-39*01 91.29 D1-26*01 72.72 J6*02 91.93 C A R H S C Y S A G C R Y Y Y G M D V W   IgG 18 
62 061221 24 V4-4*02  91.48 D2-15*01 76.92 J3*02  90.00 C V R F I G Y C N G G S C P Y G F D I W   IgG 18 
63 070510 23 V4-59*01 87.41 D3-3*01  76.92 J3*02 92.00 C A R A R V Y D F W G G R Y D A F D I W   IgG 18 
64 061213 42 V5-51*01 90.32 D1-26*01 57.89 J1*01  90.38 C A R V E G T M R T G I F Y G A Y F L H W   IgG 19 
65 070116 12 V5-51*01 68.57 D3-22*01 70.96 J3*02 94.00 C A R R Y Y Y D D D G Y S F R A A F D I W   IgG 19 
66 070116 19 V4-59*01 94.07 D3-10*01 78.94 J6*02 79.03 C A R D R Y Y G S G S F V W R G G M D V W   IgG 19 
67 070116 36 V4-39*01 90.62 D5-5*01  94.11 J4*02  91.66 C A R H E S V G D P V R G Y S N G Y P F D Y W   IgG 21 
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68 061206 21 V1-2*02 91.11 D5-5*01  76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
69 061206 26 V1-2*02 91.11 D5-5*01  76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
70 061213 3 V1-2*02 91.11 D5-5*01  76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
71 061213 8 V1-2*02 91.11 D5-5*01  76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
72 061213 14 V1-2*02 91.11 D5-5*01  76.00 J6*02  82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
73 061213 16 V1-2*02 91.11 D5-5*01  76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
74 061213 13 V1-2*02 91.11 D5-5*01  76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
75 070510 6 V1-2*02 91.11 D3-10*01 76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
76 070510 10 V1-2*02 91.11 D3-10*01 76.00 J6*02 82.25 C A R N T Y Y F G S G S V S N Y S Y C A M D V W    id  IgG 22 
77 070521 22 V1-2*02 91.67 D5-5*01  76.00 J6*02 85.71 C A R N T Y Y F G S G S V S D Y F Y Y A M D V W    di  IgG 22 
78 070521 23 V1-2*02 91.67 D5-5*01  76.00 J6*02 85.71 C A R N T Y Y F G S G S V S D Y F Y Y A M D V W    di  IgG 22 
79 061213 10 V5-51*01  87.59 D2-2*01  n.d. J6*02  85.48 C A R H Q V A P S G H A P S G V Y Y Y H G M D V W   IgG 23 
80 070510 26 V1-69*06 92.80 D3-16*02 60.00 J6*02 80.64 C A R G L N Y L D T N G S P A D S Y Q Y T L D V W   IgG 23 

















No Date of LM Cell V name Identity D name Identity J name Identity CDR3 sequence heavy chain Isotype CDR3 length 
IBM-2 
(373/96)                       
1 070402 15 V3-30*18 89.13 D3-10*02 100.00 J4*02 85.41 C A K E E V A F D Y W   IgG 9 
2 070402 12 V1-18*01 89.63 D3-16*02 75.00 J4*02 87.50 C A R V G R T I F D Y W   IgG 10 
3 070326 17 V3-33*03  91.11 D1-1*01  n.d. J6*03  68.52 C A K K G L Q R A L D V W   IgG 11 
4 070326 13 V4-59*01  89.26 D7-27*01 71.43 J3*01 88.00 C A R A G G I Y A F D V W                             id   IgG 11 
5 070326 26 V4-59*01  89.26 D7-27*01 71.43 J3*01 88.00 C A R A G G I Y A F D V W                             id  IgG 11 
6 070326 19 V1-2*02 86.23 D1-7*01 66.66 J3*01 84.00 C A G A R S R L N G F D V W  IgG 12 
7 070402 19 V1-2*02 92.11 D7-27*01 75.00 J5*02 80.39 C A L G P R G R G G P D Q W   IgG 12 
8 070402 20 V1-2*02 86.96 D2-2*01 57.14 J3*02 82.00 C A G A K S R L N G F E I W   IgG 12 
9 070326 9 V3-9*01 95.24 D6-13*01 60.00 J4*02  87.50 C A K D G T S T S W Y L D Q W                         id  IgG 13 
10 070326 16 V3-9*01 95.24 D6-13*01 60.00 J4*02  87.50 C A K D G T S T S W Y L D Q W                         id  IgG 13 
11 070402 17 V3-9*01 95.24 D6-13*01 60.00 J4*02 87.50 C A K D G T S T S W Y L D Q W                         id  IgG 13 
12 070402 10 V3-9*01 95.24 D6-13*01 60.00 J4*02 87.50 C A K D G T S T S W Y L D Q W                         id  IgG 13 
13 070402 26 V3-9*01 95.24 D6-13*01 60.00 J4*02 87.50 C A K D G T S T S W Y L D Q W                         id  IgG 13 
14 070326 10 V1-3*01 92.63 D6-19*01 80.00 J4*02 81.25 C A R E V D S S G W F F V Y W   IgM 13 
15 070326 8 V5-51*01 97.83 D6-6*01 100.00 J5*01 86.27 C A R E Y S S S S A W F D S W   IgM 13 
16 070402 1 V3-11*01 87.81 D3-16*02 68.75 J4*02 83.33 C G R E R D R Y T A G T F N Y W   IgG 14 
17 070402 9 V3-30*03 91.67 D6-19*01 52.38 J1*01 78.84 C A K D R S A V A G G P S D F P R W   IgG 16 
18 070326 12 V4-34*01  90.37 D3-22*01 56.25 J6*02  85.48 C A R G R A G S G W S Y Y Y Y V M D V W   IgG 18 
19 070402 6 V3-23*04 93.70 D3-3*01 71.42 J4*01 85.41 C A K D D G H D F W S G H G L L V D Y W   IgG 18 
20 070326 7 V1-69*01  90.91 D2-15*01 73.33 J5*02  90.19 C A R E V V A T G I P P P G W G W F D R W   IgG 19 
21 070402 23 V3-49*03 93.73 D3-3*01 91.66 J6*04 77.77 C T R D Y Y V L R F L E W V P I G M D V W   IgG 19 
22 070326 22 V4-b*01 89.96 D3-22*01 84.00 J4*02 89.58 C V R D S T H N S Y D S S G Y R N L D Y W             id  IgM 19 
23 070402 24 V4-b*01 89.96 D3-22*01 84.00 J4*02 83.33 C V R D S T H N S Y D S S G Y R N L D Y W             id  IgM 19 
24 070402 3 V3-23*01 92.31 D4-23*01 70.00 J4*02 91.66 C A N R G V P H C V R L D C S G Y F D Y W   IgG 19 
25 070326 21 V5-a*01 92.59 D6-6*01 94.44 J6*02  82.25 C A R L G I A A R P G V G P L Y N G M D V W   IgG 20 
26 070326 14 V1-69*06  86.23 D2-21*02 71.42 J3*02  88.00 C A R G G H I A L V T A T S L P R D P F D I W   IgG 21 
27 070402 5 V3-15*01 88.64 D6-13*01 52.38 J6*04 96.82 C A T F L A S A A G T D Y Y Y Y Y Y G M D L W   IgG 21 






No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype  CDR3 length 
IBM-3  
(379/96)                       
1 070118 5 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
2 070118 14 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
3 070118 21 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
4 070118 1 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
5 070118 5 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
6 070118 10 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
7 070118 11 V3-15*01 93,97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
8 070118 12 V3-15*01 93,97 D4-23*01 69.23 J1*01 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
9 070118 14 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
10 070118 17 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
11 070118 18 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
12 070118 20 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
13 070118 21 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
14 070118 22 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
15 070118 23 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
16 070118 24 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
17 070118 25 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
18 070118 26 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
19 070118 28 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
20 070118 29 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
21 070118 31 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
22 070118 30 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
23 070118 32 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
24 070207 1 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
25 070207 7 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
26 070207 8 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
27 070207 10 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
28 070207 11 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
29 070207 12 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
31 070207 19 V3-15*01 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id   IgM 13 
32 070207 20 V3-15*02 93.97 D4-23*01 69.23 J4*02 77.08 C N V V G R D G G S S S P H W                       id  IgM 13 
30 070207 18 V3-74*02 95.45 D2-15*01 84.21 J4*02  87.50 C A R G V C S G G T C L G Y W                       id  IgM 13 
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33 070207 5 V3-74*02 95.45 D2-15*01 84.21 J4*02  87.50 C A R G V C S G G T C L G Y W                       id  IgG 13 
34 070118 13 V3-21*01 91.85 D3-22*01 67.74 J5*02  90.20 C A K A A P Y D S S G Y Y L Y N Y F D P W   IgG 19 
35 070207 32 V3-9*01  93.00 D2-15*01 71.42 J5*02 94.11 C V K E P R D C R D G D C Y R N W F D P W   IgG 19 
36 070118 6 V1-69*01 88.62 D6-13*01 63.16 J6*02  82.26 C A R E A P E G D C T T I S C Y R Y N G M D V W     id  IgG 22 
37 070118 27 V1-69*01 88.62 D6-13*01 63.16 J6*02  82.26 C A R E A P E G D C T T I S C Y R Y N G M D V W     id  IgG 22 
38 070118 28 V1-69*01 88.62 D6-13*01 63.16 J6*02  82.26 C A R E A P E G D C T T I S C Y R Y N G M D V W     id  IgG 22 






















No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
IBM-4  
(323/06)                       
1 070625 17 V1-46*01 90.58 D3-9*01 75.00 J5*02 76.47 C A G A L L D N G V W A W   IgM 11 
2 070704 7 V4-61*01 87.02 D4-17*01 72.73 J4*02 75.00 C A R S T W V A T Y I F W   IgG 11 
3 070625 8 V4-61*01 87.33 D5-12*01 66.66 J5*02 96.07 C A R G L N L L N W F D P W   IgG 12 
4 070625 10 V4-31*03 95.04 D6-19*01 86.66 J4*02 85.41 C A R R N G W Y L P D D Y W   IgG 12 
5 070704 8 V5-51*01 92.03 D5-5*01 64.29 J4*02 85.42 C V R R D T N L A S G D H W  IgG 12 
6 070704 14 V3-73*01 91.49 D6-6*01 66.67 J4*02 89.58 C T R R A W D G S S P F D Y W  IgG 13 
7 070808 12 V1-69*01 90.00 D6-13*01 69.23 J4*02 85.42 C A R Q Q A L S P T G L E S W  IgG 13 
8 070808 23 V3-9*01 94.20 D4-17*01 n.d. J5*02 82.35 C A K A R N S D E G M L E D W  IgG 13 
9 070625 27 V1-18*01 89.24 D2-15*01 72.72 J4*02 87.50 C A T T D C T G G S C Y G D R W   IgG 14 
10 070704 3 V1-3*01 90.74 D6-25*01 80.00 J4*02 91.67 C A R Q G L M R R Q S S F D Y W  IgG 14 
11 070704 12 V1-2*04 89.01 D6-13*01 72.22 J4*02 87.50 C A R G G S R W Y T L N W D Y W  IgG 14 
12 070625 4 V4-59*01 88.41 D4-23*01 66.66 J5*02 92.15 C A R G G G F R W T N S G F D P W   IgG 15 
13 070625 19 V4-34*12 91.45 D6-19*01 57.14 J4*02 81.25 C A R L C C R S A C P G G V D Y W   IgG 15 
14 070625 23 V2-5*10 83.52 D6-19*01 71.42 J3*02 94.00 C A R F T A V A G T L E A F D I W   IgG 15 
15 070625 30 V3-23*04 90.00 D5-12*01 63.63 J5*02 88.23 C A K G F G S G F R G G W F D P W   IgG 15 
16 070625 3 V3-33*01 95.97 D1-26*01 61.53 J3*02 98.00 C A R R E L G S F Y A N D A F D I W   IgG 16 
17 070625 12 V1-69*11 64.14 D2-21*01 62.50 J6*02 69.35 C A R V I G P K P V V A I G M D V W   IgG 16 
18 070625 32 V3-33*01 94.44 D3-22*01 56.25 J4*02 87.50 C A R D V G H F W Q V G L G L D Y W   IgG 16 
19 070625 1 V3-64*02 93.12 D6-13*01 57.14 J4*02 97.91 C A R V A S G A A G T W N Y F D Y W                  id  IgM 16 
20 070625 33 V3-64*02 93.12 D6-13*01 57.14 J4*02 75.00 C A R V A S G A A G T W N Y F D Y W                  id  IgM 16 
21 070704 2 V1-18*01 92.22 D6-6*01 77.78 J4*02 89.58 C A R V W L A G R P A P R K I D Y W  IgG 16 
22 070808 28 V4-59*03 91.21 D6-6*01 66.67 J4*02 93.75 C A R M K Y S S T S G G Y S F D S W  IgG 16 
23 070808 11 V1-18*01 91.11 D4-17*01 75.00 J4*02 87.50 C A R G R G G P Y G D Y A V F D F W  IgG 16 
24 070704 15 V4-39*01 89.96 D3-10*01 55.17 J4*02 89.58 C A R A T P M L R G V V S L Y F V D W  IgG 17 
25 070704 18 V3-23*01 90.74 D1-20*01 76.47 J3*01 92.00 C A K D L N K W N D L D H D T F D V W  IgG 17 
26 070808 5 V3-9*01 91.29 D2-2*01 52.00 J4*02 87.50 C A K D N V P H P G A S R S R F D S W  IgG 17 
27 070808 22 V1-18*01 90.84 D3-22*01 64.00 J4*02 91.67 C A R D L P Y Y Y D K S G R V A L D Y W              di  IgG 18 
28 070625 14 V1-18*01 79.07 D3-16*01 59.09 J4*02 87.50 C A R D L P Y N Y D N V G I V S L D S W              di  IgG 18 
29 070808 13 V1-69*01 91.23 D5-24*01 n.d. J4*02 95.83 C A R A P G G F L E R G G A Y Y F D F W  IgG 18 
30 070704 6 V3-23*04 89.82 D3-3*01 82.76 J4*02 97.92 C A K K G R I T S F G V V I P D Y F D H W  IgG 19 
31 070704 11 V1-46*01 66.27 D7-27*01 63.64 J6*02 74.19 C A T N S Q A W D V P T V T S W T M A V W            di  IgG 19 
32 070808 2 V1-46*01 84.59 D7-27*01 63.64 J6*02 74.19 C A T N S Q A W D V P T V T S W T M A V W            id  IgG 19 
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33 070808 4 V1-46*01 73.76 D7-27*01 63.64 J6*02 74.19 C A T N S Q A W D V P T V T X W T M A V W            id  IgG 19 
34 070808 30 V3-21*01 68.97 D5-24*01 n.d. J6*02 88.71 C A R D Q I F P R S G G H F Y Y G M D V W  IgG 19 
35 070625 18 V3-9*01 94.33 D6-13*01 66.66 J3*01 94.00 C A K D I E E L G I A A T F L F T A F D V W   IgG 20 
38 070808 14 V3-33*01 94.62 D3-10*02 n.d. J6*02 85.16 C A R D R F V G D A P E H F Y Y Y G M D V W  IgG 20 
36 070704 34 V1-18*01 89.19 D3-16*02 n.d. J4*02 100.00 C A R A L R D D D I R G T Y H E Y Y F D Y W   IgG 20 
37 070704 20 V1-18*01 91.40 D1-26*01 60.00 J4*01 91.67 C T R I R V G V G R L G G V V G F Y Y F E Y W  IgG 21 
39 070808 10 V1-69*06 94.81 D6-19*01 76.19 J6*02 91.94 C A K S A S I P V P G K M Y F Y Y Y G M D V W  IgG 21 
40 070625 31 V3-23*04 94.79 D3-16*01 53.84 J6*02 87.09 C A K D E N I M T V V G G G G S L H Y Y G L D V W   IgG 23 
41 070808 17 V1-24*01 90.91 D2-21*02 n.d. J6*02 83.87 C A R V R V R V T R G L T G R T S L Y Y G L D V W  IgG 23 
42 070808 7 V4-61*01 89.14 D5-5*01 70.00 J2*01 88.68 C A R S R E R I Q V W S R S P R S S G G Y F D L W  IgG 23 
43 070704 5 V3-33*01 91.85 D3-22*01 67.74 J4*02 95.83 C A R D S S T M N H Y G S S V Y Y G S G S N S L D Y W  IgG 25 
44 070704 29 V3-9*01 n.d.  D4-17*01 n.d.  J5*02 90.20 C A K D I F W R S A Q R N H G D Y I D G E S A F D R W  IgG 25 


















No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
IBM-5 
(243/06)                 
1 070815 16 V3-74*02 94.79 D5-24*01 71.43 J4*02 83.33 C Q S S I H L G G W   IgG 8 
2 070711 8 V4-59*01 92.98 D5-24*01 100.00 J5*02 86.27 C T R V S T H F D P W   IgG 9 
3 070815 26 V3-23*04 87.32 D7-27*01 72.73 J4*02 85.42 C T T L S R G P G T D Y W   IgG 11 
4 070711 4 V1-46*03 90.26 D6-25*01 76.92 J4*02 95.83 C V R E G S G Y K Y F D Y W   IgG 12 
5 070711 20 V3-30-3*01 89.86 D4-23*01 75.00 J1*01 69.23 C A R S T V V L G A T R H W   IgG 12 
6 070711 27 V1-46*03 93.41 D6-19*01 76.92 J4*02 85.42 C A R D S S D F E V F A Y W   IgG 12 
7 070815 22 V3-9*01 85.66 D7-27*01 100.00 J6*02 91.94 C A K S R G D Y Y Y G L D V W   IgG 13 
8 070815 6 V2-26*01 90.04 D7-27*01 72.73 J4*02 91.67 C A R I R P Q L G P D V F D F W   IgG 14 
9 070815 13 V3-7*01 87.96 D3-3*01 54.17 J4*02 87.50 C V P Q L S F E W F K D L A S W   IgG 14 
10 070711 32 V1-8*01 95.93 D2-15*01 71.43 J3*02 92,00 C A R D C T Y D S C R E A F D I W   IgM 15 
11 070717 20 V3-30*03 96.01 D6-25*01 91.94 J6*02 62.50 C A R P R A P D Y Y Y Y G M D V W   IgG 15 
12 070717 30 V4-39*01 90.11 D1-1*01 92.16 J5*02 76.92 C A R R T P T T S S R P W F D P W   IgG 15 
13 070815 2 V3-23*04 74.40 D1-14*01 60.00 J4*02 93.75 C A R A S T S F S V R H F F D S W   IgG 15 
14 070815 10 V3-23*01 74.40 D3-3*02 52.36 J4*02 93.75 C A R A S T S F S V R H F F D S W   IgG 15 
15 070711 26 V3-33*01 89.86 D2-2*01 80.00 J4*02 81.25 C S R S R Y C S N T T C P P G D V W   IgG 16 
16 070717 9 V3-7*01 92.22 D6-13*01 89.58 J4*02 61.90 C T S R P S D V S W Y L G V F D Y W   IgG 16 
17 070815 3 V4-61*02 86.55 D1-26*01 58.82 J4*02 79.17 C A R A P R S P R G N F L P Y D F W   IgG 16 
18 070815 8 V3-23*01 93.12 D3-10*02 66.67 J3*02 86.00 C A K D P S G G T V T G G R A F E I W   IgG 17 
19 070711 1 V4-39*06 93.84 D2-2*01 64.29 J5*02 92.16 C A R D V L A V V P D G I K D W F D P W   IgG 18 
20 070815 5 V1-18*01 92.14 D3-10*01 56.25 J6*02 85.48 C A R D H A R F G D L L Y Q S G M D V W   IgG 18 
21 070815 28 V1-18*01 93.75 D4-23*01 92.31 J3*01 74.00 C V R D G A N S A P Q Y F Y Y G M D V W   IgM 18 
22 070815 23 V3-21*01 87.64 D2-8*01 63.16 J6*03 91.94 C A R D L S Q W T G D Q D Y Y Y Y M D V W   IgG 19 
23 070711 13 V4-61*02 91.40 D3-22*01 70.97 J4*02 93.75 C A R V Q G S F D G S G Y S S V D Y F D S W   IgG 20 
24 070717 32 V3-30*18 92.86 D5-24*01 82.26 J6*02 82.26 C A K G E G D P I Y S W L G Y F Y G M D V W id  IgG 20 
25 070717 23 V3-30*18 92.86 D5-24*01 82.26 J6*02 82.26 C A K G E G D P I Y S W L G Y F Y G M D V W id  IgG 20 
26 070717 26 V1-2*02 92.67 D2-2*01 92.16 J5*02 64.52 C A R A E G S C S S V S C A R F N W F D P W   IgG 20 
27 070717 6 V4-61*02 90.03 D2-21*01 93.55 J6*03 60,00 C A R A G G D G D Q L L T Y S Y Y Y M D V W   IgG 20 
28 070815 14 V3-23*01 87.92 D5-5*01 90.00 J6*02 88.71 C A K A R G Y S Y G F D D D Y Y Y A M D V W   IgG 20 
29 070717 11 V4-59*02 89.89 D4-23*01 88.71 J6*03 57.89 C A R G R S N R M G S H F G N N Y Y Y M D V W   IgG 21 
30 070717 12 V4-61*02 89.74 D3-22*01 82.26 J6*02 77.27 C A R A G D F H D T S G F C P S C Y G L D V W   IgG 21 
31 070815 4 V4-59*01 91.58 D3-3*01 80.00 J6*03 90.32 C A R D R I D T I F G V V S H S Y Y Y M D V W   IgG 21 
32 070815 11 V4-61*02 71.13 D2-2*01 62.96 J3*02 94.00 C A K T X R D G D S D P V P V P I E A F D I W   IgG 21 
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No Date of LM Cell V name Identity D name Identity J name Identity CDR3 sequence heavy chain Isotype CDR3 length 
PM-1  
(350/95)                       
1 070226 3 V3-7*01  90.22 D6-13*01 100.00 J4*02  79.16 C T S G H Y G C W   IgG 7 
2 070219 18 V3-73*01 90.22 D1-26*01 66.66 J4*01 75.00 C T K M G F T T E N F W                               id  IgG 10 
3 070219 34 V3-73*01 90.22 D1-26*01 66.66 J4*01 75.00 C T K M G F T T E N F W                               id  IgG 10 
4 070214 17 V1-69*06  89.26 D2-21*01 n.d. J6*02  81.03 C S R D R Y S D G M D V W                             id  IgG 11 
5 070214 18 V1-69*06  89.26 D2-21*01 n.d. J6*02  81.03 C S R D R Y S D G M D V W                             id  IgG 11 
6 070219 32 V5-51*01  89.49 D1-1*01  72.72 J4*02  91.66 C V R R P T R G Q F D S W   IgG 11 
7 070226 23 V1-24*01 97.83 D3-16*01 n.d. J6*02  79.03 C V R G L R E Y V M D V W   IgG 11 
8 070219 40 V4-31*01 89.71 D2-15*01 72.72 J2*01 83.01 C A R G F W K V G S F D L W   IgG 12 
9 070307 5 V4-59*01 87.50 D4-11*01 100.00 J5*01 82.35 C A R D L M T T D R G F D L W   IgG 13 
10 070110 3 V5-51*01 92.59 D2-15*01 55.55 J5*02 94.11 C A R H S S L D L S S W F D P W                       id  IgG 14 
11 070110 4 V5-51*01 92.59 D2-15*01 55.55 J5*03 94.11 C A R H S S L D L S S W F D P W                       id  IgG 14 
12 070214 13 V1-69*01 90.53 D6-13*01 69.23 J3*01 88.00 C A H Q T G Y S L S A T F D V W   IgG 14 
13 070307 8 V3-9*01  95.70 D3-10*01 83.33 J6*02 87.09 C V K S G Y F S Y F Y S M D V W   IgG 14 
14 070214 25 V1-46*01  88.15 D3-16*01 62.50 J6*02  90.32 C V R G G A Q T Y Y Y H G M D V W   IgG 15 
15 070214 28 V3-23*01 92.31 D4-17*01 66.66 J2*01 96.22 C A K R R G D Y F P D W Y F D L W   IgG 15 
16 070219 37 V3-9*01  97.44 D3-22*01 80.00 J6*02  83.87 C A K D S C G G G S C Y G M D V W   IgG 15 
17 070226 15 V4-61*08 94.93 D4-4*01  75.00 J5*02 100.00 C A R A H T T T T T D N W F D P W   IgG 15 
18 070214 16 V1-18*01  91.57 D6-19*01 62.50 J5*02  96.07 C G R M L V G G A W F G N W F D P W   IgG 16 
19 070214 19 V4-31*06 88.61 D3-16*01 60.00 J6*02  83.87 C A R V S P P R G T Y Y Y S M D V W   IgG 16 
20 070214 33 V4-34*01 92.88 D4-23*01 63.15 J5*02 92.15 C A R G R L F G G T F H N W F D P W   IgG 16 
21 070226 9 V5-51*01  72.34 D3-22*01 70.00 J6*02  80.64 C A R Q M R V G G T P N H G M D V W                   id  IgG 16 
22 070226 12 V5-51*01  94.87 D3-22*01 70.00 J6*02 80.64 C A R Q M R V G G T P N H G M D V W                   id  IgG 16 
23 070214 4 V1-69*04  86.96 D2-15*01 76.00 J4*02  87.50 C S R S P F E G Q C F G G R C W Y L D S W   IgG 19 
24 070307 12 V3-30-3*01 98.17 D5-24*01 66.66 J6*02 95.16 C A T P T P D E M G Y F Y Y Y H G M D V W   IgM 19 
25 070214 31 V3-7*01 95.93 D6-13*01 68.42 J4*02  97.91 C A R G R S S W T P W A T R T D Y F D F W   IgG 19 
26 070226 17 V1-69*01 88.15 D2-15*01 75.00 J6*02  83.87 C A R G P G Y F N G D R F F Y N G L D V W   IgG 19 
27 070214 9 V3-9*01  88.15 D2-2*03  70.00 J5*02  92.15 C A K D F G S S V A I V A G S I H Y F D P W   IgG 20 
28 070214 26 V5-51*01  87.68 D3-10*01 77.41 J4*02  81.25 C V R H G A W Y G S E S N Y N V G L L D Y W   IgG 20 
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29 070214 6 V4-59*02 88.52 D3-22*01 74.19 J4*02  93.75 C A R L R R A P H Y D S T G Y Y H T Y F F D Y W       di  IgG 22 
30 070307 9 V4-59*02 89.74 D3-22*01 77.41 J4*02  97.91 C A R L R R A P H Y D S T G Y Y H T Y F F D Y W       di  IgG 22 
31 070110 8 V3-9*01  92.98 D3-3*01  89.47 J6*02 85.48 C A R D K G R E F Y D F W S G H S Y H F G M D V W   IgG 23 























No Date of LM Cell V name Identity (%) D name Identity (%) J name Identity (%) CDR3 sequence heavy chain Isotype CDR3 length 
PM-2  
(249/06)                       
1 070725 12 V4-30-2*01 88.44 D2-21*02 77.78 J4*02 91.67 C V R R R D S Y Y D Y W   IgG 10 
2 070719 7 V3-30*04 86.36 D7-27*01 100.00 J3*02 76.03 C A K G D A A G A M D N W   IgG 11 
3 070725 6 V4-59*01 91.49 D2-15*01 75.00 J5*02 72.55 C A R V S L G R G A L N W   IgG 11 
4 070725 7 V1-2*02 88.41 D6-25*01 75.00 J4*02 87.50 C F I S G Y D S V L D F W   IgG 11 
5 070719 16 V3-23*01 88.53 D4-17*01 66.67 J4*02 83.33 C A K N P D D Y S I F D F W   IgG 12 
6 070719 22 V1-46*01 88.89 D6-13*01 100.00 J6*03 80.65 C A R G S S Y T H Y M D V W   IgG 12 
7 070719 28 V3-33*01 96.63 D6-25*01 83.33 J4*02 100.00 C A R D R Y S S D Y F D Y W   IgG 12 
8 070725 9 V1-18*01 96.88 D3-22*01 71.43 J4*02 97.92 C A R G R R L L K Y F D Y W   IgG 12 
9 070725 16 V3-43*01 93.50 D3-16*02 63.64 J4*02 85.42 C A K D M G G D R L L D S W   IgG 12 
10 070719 15 V3-23*01 90.04 D1-14*01 61.54 J3*02 90.00 C A R Q D I S G P T A F D M W   IgG 13 
11 070725 22 V5-51*01 95.97 D6-19*01 100.00 J4*02 83.33 C A R S R R G I A V A A D Y W   IgG 13 
12 070719 2 V3-23*04 95.34 D1-1*01 87.50 J4*02 100.00 C A K D S N W N D P N Y F D Y W   IgG 14 
13 070719 14 V4-59*01 95.88 D3-10*01 55.00 J4*02 75.00 C A R G G A R G I F S P L T A W   IgG 14 
14 070719 5 V3-23*01 96.97 D6-25*01 73.33 J4*02 87.50 C A K D P E H N S S G A T V D Y W   IgG 15 
15 070719 33 V3-74*01 99.63 D3-16*02 66.67 J4*02 81.25 C A R D R E T A L G G A G V D Y W   IgM 15 
16 070725 14 V3-7*02 91.48 D3-22*01 62.50 J4*02 89.58 C A R R G H S S G S Y R P F D Y W   IgG 15 
17 070725 4 V1-18*01 87.50 D1-14*01 60.00 J4*02 97.92 C A T G L F T G I I S T H Y F D S W   IgG 16 
18 070725 5u V7-4-1*02 91.85 D2-15*01 82.76 J3*01 78.00 C A R G K Y C S G G N C Y G R Y W D F W           id  IgG 18 
19 070725 2 V7-4-1*02 91.23 D2-15*01 82.76 J3*01 78.00 C A R G K Y C S G G N C Y G R Y W D F W           id  IgG 18 
20 070719 32 V4-59*01 96.30 D2-2*01 70.37 J2*01 96.23 C A R A P G I L V I P P T P F W Y F D L W   IgG 19 
21 070725 18 V3-48*02 92.03 D3-22*01 62.50 J1*01 92.31 C A R D A S P E D Y S T S G D I E Y F H H W   IgG 20 
22 070719 27 V1-18*01 93.33 D5-24*01 54.55 J6*02 87.10 C A R D H V R V L V E V S D R Y K I G Y Y G L D V W   IgG 24 
 
Supplementary tables: showing in detail the results of genetic analyses of the Ig gene from isolated plasma cells from IM biopsies  
(id) identical sequences; (di) different sequences but clonal related; (bs) bad sequence
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